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MCKIBBEN, GERALD D., Ph.D. The Effect of Zinc Supplementation on 
Total Cholesterol, HDL-Cholesterol, the HDL-Cholesterol: Total 
Cholesterol Ratio, HDI_2-Cholesterol and HDl_3-Cholesterol, Serum 
Zinc and Copper Among Participants in a Progressive Exercise 
Program. (1988). Directed by Dr. Terry L. Bazzarre. 126 pp. 
The purpose of this dissertation research was to determine the 
effects of zinc supplementation on total cholesterol, HDL 
cholesterol, the HDL-cholesterol:total cholesterol ratio, HDL2 
cholesterol, HDL3 cholesterol, serum zinc and serum copper in a 
progressive exercise program. Subjects (n=47) in a weight reduction 
program received either 15 mg zinc (E) or a placebo (C) over a 12 
week period. The weight reduction program consisted of 12 lifestyle 
management workshops and 36 activity sessions. Blood samples 
were drawn at week 0 and week 12 and analyzed for total 
cholesterol, HDL cholesterol, HDL2-cholesterol, HDL3-cholesterol, 
copper and zinc. Mile walk times were assessed at both week 0 and 
week 12 in order to measure fitness. To be consistent, 
nonparametric statistical tests were used to test all hypotheses. 
Based on final results, zinc supplementation (15 mg) did not 
significantly affect lipid status. Significant (p<0.05) changes during 
the study included decreased percent body fat (-1.1 ±.1.5 percent 
body fat difference) among control females, decreased walk time for 
experimental (-1.23 ± 1.71 minutes difference) and control (-1.10 ±. 
1.10 minutes difference) females, increased HDL-C (5.6 ± 2.3 mg% 
difference) for experimental males, increased HDL2 (7.7 ± 7.7 mg% 
difference) for control females, decreased HDL3 for experimental 
(-13.9 ±. 12.7 mg% difference) and control (-16.3 ±. 20.4 mg% 
difference) females, decreased serum zinc (-37 ±_ 27 ug/dl 
difference) for experimental females, decreased serum copper (-33 
±. 20 ug/dl difference) for control males and experimental) females 
(-39 ±_ 27 ug/dl difference). Significant positive correlations 
occurred between final serum zinc and both final HDL-C (r=0.89; 
p=0.007) and final HDL2 cholesterol (r=0.87; p=0.01), between initial 
serum zinc and initial HDL3 cholesterol for females (r=0.47; p=0.03), 
between the zinc/copper ratio difference and HDL-C:TC ratio 
difference for control males (r=0.81; p=0.02). Significant negative 
correlations were observed between initial walk time and initial 
HDL-C for females (r=-0.44; p=0.04) and between initial HDL3 
cholesterol and initial walk time for males (r=-0.73; p=0.03). In 
summary, zinc supplementation (15 mg/day) had no significant 
effect on cholesterol levels. Zinc and copper status decreased for all 
groups during the weight reduction program. Because of the lack of a 
sufficient number of returned diet records, it could not be 
established whether diet, exercise or the combined interaction of 
diet and exercsie induced the observed decline in zinc and copper 
status. 
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CHAPTER I 
INTRODUCTION 
An increasing number of Americans are consuming vitamin and 
mineral supplements, either in doses that approximate the RDA or in 
"mega dose" (>10 times the RDA) formulations. The potential health 
benefits of such practices are unproven and largely uninvestigated. 
Zinc Supplementation 
Zinc supplementation has been recommended to improve wound 
healing, for disorders of taste and smell, to improve sexual potency, 
and for the treatment of acne (Walravens, 1971). Recent reports 
have indicated that daily administration of 440 mg of zinc sulfate 
(160 mg of elemental zinc) to individuals over age 70 resulted in a 
marked improvement in such immune parameters as delayed-type 
hypersensitivity responses to skin testing, number of circulating T 
cells, and IgG response to tetanus vaccine. (Duchateau, Delepesse, 
Brijens, 1981). These scientific reports have been translated in the 
lay press into enthusiastic endorsements of zinc supplementation in 
either normal or mega doses (Shaklee Zinc Fact Book, 1980). The lay 
literature especially encourages zinc supplements for those who 
exercise (Hutcheson, 1981). 
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Zinc Toxicity 
Zinc is considered a safe mineral. Zinc salts are well tolerated 
and have a large margin of safety. Nevertheless, prolonged oral 
ingestion may result in toxicity (Murphy, 1970; Moore, 1978). 
Symptoms of zinc toxicity include anorexia, vomiting, nausea, 
lethargy, dizziness, diarrhea, muscle pain, and bleeding gastric 
ulcers (Moore, 1978; Donaldson, 1980; Aggett & Harries, 1979). 
Some symptoms can occur after the ingestion of a 220 mg capsule 
(Glover & White, 1977). In addition, zinc may interfere with copper 
metabolism (Prasad, Brewer, Schoolmaker, & Rabbani, 1978). 
Zinc and Lipid Metabolism 
Although the mechanisms are unknown, a high zinc to copper 
ratio is associated with elevated cholesterol in experimental 
animals (Klevay, 1973). Furthermore, high intakes of zinc reportedly 
reduce high density lipoprotein cholesterol (HDL-cholesterol) 
(Hooper, Garry & Goodwin, 1982). HDL-cholesterol is often referred 
to as "good cholesterol" because the elevated HDL-cholesterol is 
negatively correlated with an increased incidence of heart disease 
(Wilson, 1980). While the direct effect of excess Zn:Cu ratio on 
coronary heart disease has not been established by clinical studies, 
Klevay's research (1975) suggests that the high Zn:Cu ratio may 
produce unfavorable changes in cholesterol metabolism; cholesterol 
is a major risk factor for coronary heart disease. 
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Purpose of the Study 
The overall purpose of this study was to determine the effects 
of zinc supplementation on total cholesterol, HDL cholesterol, the 
HDL-C:TC ratio, HDL2 cholesterol, HDL3 cholesterol, serum zinc and 
serum copper in a progressive exercise program. 
Rationale of the Study 
The rationale for this study is based on the premise that obese 
subjects are at increased risk of coronary heart disease, 
hypertension and diabetes. Exercise has been demonstrated by 
Bazzarre et al. (1985) in conjunction with a nutrition education 
lifestyle management program to not only be an effective method of 
promoting weight/fat loss but also to produce favorable alterations 
in chronic disease risk factors such as cholesterol/lipid profiles and 
blood pressure. 
The results by Kennedy, Failla and Smith (1986) and Chandra and 
Kutty (1980) suggesting that obese subjects may be at risk of 
marginal zinc deficiency; results by Spencer, Kramer, Perakis, 
Norris and Osis (1982) suggesting that weight loss may be 
associated with the induction of zinc deficiency; and results by 
Dressendorfer and Sockolov (1980) suggesting that exercise training 
reduces zinc status all suggest that obese subjects on a 
diet/exercise/weight loss regimen should receive zinc 
supplementation or at least be evaluated on an individual basis for 
signs and symptoms of zinc deficiency. While zinc supplementation 
of obese subjects during a weight loss program may be advisable, it 
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is important that the level of supplementation not reverse favorable 
changes in lipid profiles. No research has been conducted in an obese 
population during a weight loss program to determine if a low dose 
zinc supplement would prevent the development of zinc deficiency 
but not affect the expected favorable changes in lipid profiles. 
Objectives 
The specific objectives of the 12-week study were the 
following: 
(1) To measure fasting total cholesterol (TC), HDL-C and the 
HDL-C: TC ratio as well as plasma zinc and copper of experimental 
and control subjects at weeks 0 and 12. 
(2) To measure the effects of activity/fitness on serum zinc 
status of experimental and control subjects at weeks 0 and 12. 
(3) To measure the relationship between serum zinc and TC, 
HDL-C and HDL-C:TC ratio, HDL-2, HDL3 and obesity among 
experimental and control subjects at weeks 0 and 12. 
(4) To measure the relationship between serum zinc/copper 
ratio and the HDL-C:total cholesterol ratio at weeks 0 and 12. 
Hypotheses 
In the following hypotheses, E represents the experimental 
subjects participating in a 12 week exercise program who received 
Zn supplementation (15 mg Zn/day) during the 12 weeks. C 
represents control subjects receiving no Zn supplementation but 
participating in the exercise program. E:C represents the 
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comparative evaluation of significant differences between the 
means for the experimental subjects and control groups. 
Total Cholesterol (TC) 
tLl^E: TC is noi significantly different at week 0 versus week 12 
among experimental subjects. 
TC is signficantly different at week 0 versus week 12 
among control subjects. 
Hi-E:C: TC is significantly different between experimental and 
control subjects at week 12. 
HDL Cholesterol (HDL-C^ 
JI2E1 HDL-C is no! significantly different at week 0 versus week 
12 among experimental subjects. 
JI2C.: HDL-C is significantly different at week 0 versus week 12 
among control subjects. 
Hg-E:C: HDL-C is significantly different between experimental 
and control subjects at week 12. 
HDL CholesterokTotal Cholesterol (HDL-C:TC) 
JI31E1 HDL-C:TC is not significantly different at week 0 versus 
week 12 among experimental subjects. 
H3-C: HDL-C:TC is significantly different at week 0 versus week 
12 among control subjects. 
H 3 - E: C: HDL-C:TC is significantly different b e t w e e n  
experimental and control subjects at week 12. 
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HDL-2 Cholesterol 
H/JE: HDL2 is nM significantly different at week 0 versus week 
12 among experimental subjects. 
H/JC: HDL2is significantly different at week 0 versus week 12 
among control subjects. 
H/]-E:C: HDL2 is significantly different between experimental 
and control subjects at week 12. 
HDL3 Cholesterol 
H5E: HDL3 is jiM significantly different at week 0 versus week 
12 among experimental subjects. 
H.5.G.: HDL3 is significantly different at week 0 versus week 12 
among control subjects. 
Hg-EiC: HDL3 is significantly different between experimental 
and control subjects at week 12. 
Correlations between Independent Variables and Blood Lipids among 
Male and Female Participants in a Progressive Exercise Program 
He: There is a positive association between serum zinc and TC 
for males and females. 
H7: There is an inverse association between serum zinc and HDL-
C for males and females. 
Hq: There is an inverse association between serum zinc and HDL-
C:TC for males and females. 
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Hg: There is an inverse association between HDL2 and serum 
zinc for males and females. 
Hiq: There is an inverse association between HDL3 and serum 
zinc for males and females. 
H-| 1: There is an inverse association between obesity and serum 
zinc for males and females. 
H12: There is an inverse association between the serum 
zinc/copper ratio and the HDL-C: total cholesterol ratio for males 
and females. 
H13: There is an inverse association between activity/fitness 
and serum zinc for males and females. 
Definitions 
Control subjects: Subjects participating in a 12 week nutrition 
education, physical fitness, lifestyle management program (the 
RESHAPE program) who received a placebo. 
Experimental subjects: Subjects participating in the 12 week 
RESHAPE program who received zinc supplementation (15 mg/day). 
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CHAPTER II 
REVIEW OF LITERATURE 
Introduction 
The following literature review provides background 
information on zinc function, deficiency and supplementation. The 
discussion also addresses characteristics of the study subjects, 
experimental designs, and the effects of zinc on lipid profiles. 
Finally, the results and conclusions of the studies included in the 
literature are reviewed and evaluated. 
Zinc Deficiency 
The essentiality of zinc (Zn) is based in part on its role as an 
integral part of a number of metalloenzymes and as a cofactor for 
regulating the activity of specific zinc-dependent enzymes involved 
in normal protein, carbohydrate, lipid and nucleic acid metabolism 
(Roth & Kirchgessner, 1980). Zinc deficiency in experimental 
animals leads to growth retardation, and deficiency during prenatal 
life can result in the abnormal development of the embryo and fetus 
(Swenerton & Hurley, 1968; Hurley, 1970). 
Prasad (1979) and, Casey and Hambidge (1980) have reported 
that zinc deficiency does occur in humans. Nutritionists are 
concerned about the zinc status of children, teenagers, pregnant 
women, vegetarians consuming high fiber diets (Swanson & King, 
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1979; Hambidge, Jacobs & Baum, 1972) and, possibly, endurance 
athletes (Dressendorfer & Sockolov, 1980). Chandra and Kutty 
(1980) have reported that obese subjects may be at risk for 
marginal zinc status; however, clear evidence of inadequate zinc 
status in the general population is lacking (Swanson et al., 1979). 
The lack of evidence seems logical since zinc is widely available in 
food from both plant and animal sources (Freeland & Cousins, 1976). 
Men who exercise regularly have a lower risk of coronary heart 
disease than men who do not exercise (Klevay, 1975). The 
concentration of zinc (0.93 mg/liter) in sweat (Prasad, Schulert, 
Sandstead, Miale & Farid, 1963) is approximately 16 times that of 
copper (0.058 mg/liter). Thus, sweating is associated with a 
relatively greater loss of zinc than copper, resulting in a lower ratio 
of plasma zinc to copper (Klevay, 1975). 
Klevay (1975) has identified a metabolic imbalance of zinc to 
copper as a major factor in the etiology of coronary heart diease. 
This metabolic imbalance is either a relative or absolute deficiency 
of copper characterized by a high ratio of zinc to copper. The 
imbalance results in hypercholesterolemia and increased mortality 
due to coronary heart disease. The elevated zincrcopper ratio results 
from imbalances in the amounts of zinc and copper consumed 
(Klevay, 1975). For example, diets associated with a high risk of 
coronary heart disease are likely to contain a high zinc to copper 
ratio and to be low in phytic acid and fiber. Both phytic acid and 
fiber are chelating agents which may prevent a high zinc to copper 
ratio by reducing zinc bioavailability (i.e., absorption). 
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Zinc and copper have been measured (Webster, 1965) in the 
uninjured, presumably healthy, myocardial tissue of victims of 
myocardial infarction and the myocardial tissue of victims of 
accidents. No difference was found in the concentration of zinc 
between the two groups; however, the concentration of copper was 
lower in tissue from hearts with infarction. Thus, the victims of 
coronary heart disease may be presumed to have a higher than 
normal ratio of zinc to copper (Klevay, 1975). 
Zinc Supplementation 
As discussed in the next section, some nutritionists have 
become concerned that excessive zinc supplementation may 
unfavorably alter lipid profiles. These reports raise the possibility 
that a mineral consumed by millions of individuals daily in 
multivitamin and mineral supplements (Read & Graney, 1981) may be 
lowering high density lipoprotein cholesterol, which is associated 
with a decreased risk of cardiovascular disease (Castelli, Doyle & 
Gordon, 1977). 
Since zinc-deficient animals exhibit impaired reproduction 
(Hurley & Swenerton, 1966), promoters of zinc supplements claim 
that large doses increase virility and improve sex drive. Zinc 
supplements are also promoted because of alleged benefits regarding 
tissue growth and repair and as a preventive measure to delay 
various aging processes. No evidence exists that zinc 
supplementation offers benefits to healthy people with adequate 
zinc intakes, the RDA being 15 mg/day for most adults (Food and 
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Nutrition Board of the National Research Council, 1980). Zinc 
supplementation may be required by young children suffering from 
the skin disease acrodermatitis enteropathica (Nelder & Hambridge, 
1975) and by patients receiving total parenteral nutrition (Arakawa, 
Tamura, Igarashi, Suzuki & Sandstead, 1976). 
Zinc and Cholesterol 
The suggestion that dietary levels of zinc and copper play an 
important role in lipoprotein metabolism was originally forwarded 
by Klevay (1973; 1975) who suggested that an increase in the ratio 
of zinc to copper in the diet caused hypercholesterolemia, leading to 
an increased risk of atherosclerosis. Subsequent work in 
experimental animals and man has produced conflicting results 
(Petering, Murthy & O'Flaherty, 1977; Looney & Lei, 1978; Caster & 
Doster, 1979; Fischer, Giroux & Belonje, 1980; Prasad, 1976; 
Sandstead, Klevay & Mahalko, 1980; Allen & Klevay, 1978; Freeland-
Graves, Han, & Friedman, 1980; Koo & Williams, 1981). 
Nevertheless, the possibility exists that a mineral consumed by 
millions of individuals daily in multivitamin and mineral 
supplements (Read & Graney, 1981) may be lowering high-density 
lipoprotein (HDL)-cholesterol. HDL-cholesterol is a marker for 
decreased risk of cardiovascular disease. (Castelli, Doyle & Gordon, 
1977). 
Mertz (1979; 1982) has concluded that no evidence currently 
links trace element status directly to cardiovascular disease; rather 
a number of trace elements apparently influence individual risk 
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factors for cardiovascular disease. Specifically, zinc 
supplementation in rats on a copper- and zinc-deficient diet was 
associated with substantial increases in serum cholesterol. 
Increasing the copper content of the diet partially counteracted the 
hypercholesterolemia effect of zinc (Klevay, 1973). The relative 
importance of zinc "excess" to copper "deficiency" to 
hypercholesterolemia is a matter of some controversy (Klevay, 
1973; Klevay, 1975; Petering et al:, 1977; Looney et al., 1978; 
Caster & Doster, 1979; Allen & Klevay, 1978). Data regarding the 
influence of zinc intake on blood lipid parameters in humans is more 
limited. Prasad (1976) reported that an experimental zinc 
deficiency in two volunteers was associated with decreased serum 
cholesterol levels, while Sanstead et al. (1980) found experimental 
zinc deficiency in a single volunteer was associated with increased 
serum cholesterol. 
Other investigators have evaluated whether altered HDL 
composition is due specifically to zinc deficiency or to reduced food 
intake (Schneeman, Lacy, Ney, Lefevre, Keen, Lonnerdal & Hurley, 
1986). Rats were placed in three groups for 21 days. The three 
groups were rats fed a zinc-adequate diet (100 ppm) ad libitum, rats 
fed a zinc-deficient diet (< 1 ppm) ad libitum, and rats fed a zinc-
adequate diet equal to the calorie intake of the zinc-deficient group 
(i.e., pair-feeding). Animals consuming the low zinc diet were zinc 
deficient. The zinc deficient diet which impaired appetite and 
reduced calorie intake was associated with lower plasma VLDL 
triglyceride levels and lower HDL cholesterol levels. The 
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similarities in the overall pattern of lipoprotein composition 
between the zinc-deficient and zinc adequate-calorie restricted 
groups indicate that reduced food intake may account for the 
differences in lipoprotein composition. 
Zinc in Weight Loss. Exercise and Obesity 
Excessive zinc loss, induced by weight loss during total 
starvation, is related to increased plasma levels of zinc (Spencer, 
Kramer, Perakis, Norris & Osis, 1982). These levels, then, do not 
reflect zinc status during catabolic states of weight loss. (Spencer 
et al., 1982). Spencer et al. (1982) arrived at this conclusion after 
monitoring plasma levels and urinary excretions in 18 total 
starvation studies carried out over 35 to 80 days in the excessively 
obese. The authors did not state how many subjects were included 
in their research. As plasma levels increased to 140 ug% (control 
levels averaged 100 ug%), urinary zinc excretion reached 4.8 mg/day 
in contrast to an average of 1.4 mg/day for controls. 
The increased plasma and urinary excretion levels Spencer et al. 
(1982) observed were probably the result of the breakdown of lean 
body tissue (Klevay, 1975). Lean body tissue is a storage site for 
zinc (Klevay, 1975). As in the following example, however, different 
conditions, e.g., intensive training, can increase urinary zinc 
excretion without increasing serum zinc. 
A similar increase in urinary zinc excretion occurred among 30 
soldiers studied during a 34-day intensive training exercise 
(Miyamura, McNutt & Wenkam, 1987). In contrast to Spencer et al. 
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(1982), serum zinc levels were depressed. According to the 
investigators, the depressed serum zinc concentrations indicated 
less zinc available to metabolically active tissue. This depression, 
they postulated, might "compromise the soldier (or the athlete) who 
must be at peak performance (physical or mental) at all times" 
(Miyamura et al., 1987). 
The difference between the two studies, i.e., Spencer et al. 
(1982) and Miyamura (1987), is probably due to two factors. The 
soldiers probably lost zinc through sweat, while the obese patients 
increased serum zinc through breakdown of lean body tissue. Lean 
body tissue is a storage site for zinc (Klevay, 1975). 
In a study of experienced runners (Dressendorfer & Sockolov, 
1980), serum zinc concentrations decreased with increased training 
distance. In addition, the redistribution of zinc stores in the body 
could explain the hypozincemia accompanying exercise. Oh, Deagan 
and Whanger (1978) observed decreased plasma zinc concentrations 
during acute endurance exercise in rats. However, this decline was 
associated with increased synthesis of metallothionein, a zinc-
binding protein. Thus, exercise training may stimulate production of 
zinc-dependent enzymes in the liver and other tissues, thereby 
lowering circulating zinc levels (Oh, Deagan & Whanger, 1978). 
Obesity may affect plasma zinc in both animals and humans 
(Kennedy, Failla & Smith, 1986; Chandra & Kutty, 1980). Chandra and 
Kutty (1980), for example, found that 38 percent of obese children 
and adolescents had a moderately lower serum zinc concentration 
than did their moderate weight counterparts. Lipid profiles were 
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not assessed in these studies. In contrast to the previous study, 
normal serum zinc concentrations were observed in 285 obese 
patients hospitalized in a department of internal medicine for acute 
or chronic conditions (Pras, Dayada, Bertrand, Lapalus, Garaffo, 
Savini & Babeau, 1983). Further research is needed in free-living 
populations in order to interpret the conflict between these studies. 
Human Studies of Zinc Supplementation on Lipid Profiles 
While various studies have investigated the relationship of zinc 
and plasma cholesterol levels among animals (Klevay, 1973; Looney 
& Lei, 1978; Murthy & Petering, 1976; Helwig, Mulmix & Regenstein, 
1978; Eisemann, Pond & Thonney, 1979), only five studies have been 
reported in the literature since 1980 which focus on the effects of 
zinc supplementation on lipid profiles of humans (Freeland-Graves, 
Han, Friedman, Shorey, 1980; Hooper, Visconti, Garry & Johnson, 
1980; Goodwin, Hunt, Hooper & Garry, 1985; Crouse, Hooper, 
Atterbom & Pappenfuss, 1984; Black, Medeiros, Brunett & Welke, 
1984). 
This final section of the review of literature represents a 
critical analysis of the design and results of these five research 
papers. The review includes a brief general description of the 
findings of each study, a review of the design of these studies (e.g., 
sample selection), a review of the various supplementation levels 
used, a review of the various methods used to monitor 
supplementation compliance, the methods used to evaluate diet, the 
methods used to collect blood samples, and the procedures used to 
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analyze lipid profiles, a review of the methods used to evaluate 
activity/exercise, a review of the methods used to measure body 
fat, and, finally, a review of the analytical methods used to measure 
statistically significant effects of zinc supplementation on lipid 
profiles. 
Hooper et al. (1980) studied the effect of administering 440 mg 
of zinc sulfate (160 mg of elemental zinc) per day for 35 days to 12 
healthy adult men. Total cholesterol remained constant, but HDL-
cholesterol decreased from 40.5 ± 6.5 mg/dL before treatment to 
33.5 ±. 5.0 mg/dL after treatment (p=.0001). While the amount of 
zinc used in this trial was quite high (~10 times the RDA), the 
results raised the question of whether lower levels of zinc 
supplementation might also be associated with decreased HDL-
cholesterol. 
Freeland-Graves et al. (1980) reported a transient decrease 
(over two weeks) in both total and HDL-cholesterol in eight women 
given 100 mg zinc (as zinc acetate) but no change in HDL-cholesterol 
with lower levels of zinc supplementation (50 mg/dL or less) during 
the 60-day study period. The level of physical activity of these 
subjects was not considered. 
Crouse et al. (1984) studied, 21 endurance trained men and 23 
sedentary men who received either a placebo or 50 mg zinc sulfate 
daily for eight weeks. Although plasma zinc increased 15 percent, 
fasting plasma high density lipoprotein cholesterol, total 
cholesterol, low density lipoprotein cholesterol and triglyceride 
levels did not change in response to zinc ingestion. The authors 
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concluded that low-dose zinc supplementation does not affect lipid 
or lipoprotein values in either endurance-trained or sedentary men. 
Goodwin et al. (1985) investigated the association between the 
level of exercise, ingestion of zinc supplements (>15 mg)/d), and 
serum high-density lipoprotein (HDL) cholesterol levels in 270 
healthy men and women over age 60. After controlling for gender, 
alcohol intake, and body mass, there was a small but significant 
positive correlation (partial r=0.26, p=0.005) between the level of 
exercise and serum HDL cholesterol in the 180 subjects not taking 
supplemental zinc. There was no correlation for those subjects 
taking supplemental zinc (r=-0.18, p=0.14). A significant 
interaction of zinc intake and activity level on HDL cholesterol was 
noted as a result of multiple regression analysis. In 22 subjects 
who were ingesting 17.5 to 52.2 mg per day (median 24 mg per day) 
of supplemental, elemental zinc daily, cessation of zinc supplements 
for eight weeks was associated with a significant increase in HDL 
cholesterol levels (2.0 mg/dL, p=0.04). The change in HDL after 
stopping zinc was positively correlated (r=0.41, p=0.05) with the 
level of exercise of the subjects. Thus, supplemental zinc ingestion 
(>15 mg/day) appears to block the exercise-induced increase in 
serum HDL cholesterol in a healthy population. No associations with 
total cholesterol were observed. 
Black et al. (1988) reported significantly lower HDL cholesterol 
levels in subjects assigned to the 75 mg group at weeks 6 and 12 
when compared to the placebo group and when compared to baseline 
values at weeks 6, 8 and 12 of the study. Subjects assigned to the 
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50 mg group had lower serum HDL cholesterol at week 12 than did 
the placebo group and lower levels at week 12 than at baseline. 
Study Parameters 
The number of subjects in the five studies was relatively small: 
20 (Hooper et al., 1980), 30 (Black et al., 1988), 32 (Freeland-Graves 
et al., 1980) and 44 (Crouse et al., 1984). Only Goodwin et al. (1985) 
evaluated a large number of subjects (n=270). Only women were 
included in one study (Freeland-Graves et al., 1980). Only men were 
included in two studies (Crouse et al., 1984; Hooper et al., 1980). 
Goodwin (1985) studied a mixed sample of males and females but did 
not evaluate any effects of gender in the data analyses. 
The ages of the subjects in these studies ranged from relatively 
young adults (Black et al., 1988; Freeland-Graves et al., 1980; 
Hooper et al., 1980) to senior adults (Goodwin et al., 1985). 
Subjects were 18-40 years old in the Freeland-Graves et al. study 
(1980) and 19-29 years in the Black et al. (1988) study. Hooper et 
al. (1980) used subjects between 23 to 35 years. Crouse et al. 
(1984) evaluated subjects 20 to 55 years of age. All subjects in the 
Goodwin et al. (1985) study were older than 60. 
Zing Dq$3, Timing and Length Qf Study 
The effects of zinc on lipids may be related to the dose used and 
the length of each study. The studies lasted 60 days (Freeland-
Graves et al., 1980), five weeks (Hooper et al., 1980), eight weeks 
(Crouse et al., 1984), and five years (Goodwin et al., 1985). 
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Zinc dose varied among these studies. Dividing subjects into 
four groups, Freeland-Graves et al. (1980) administered 0, 15, 50 
and 100 mg. zinc as zinc acetate. The supplements were ingested 
daily with the evening meal. Black et al. (1988) administered a 
placebo to one group, 50 mg zinc to a second group and 75 mg zinc to 
a third group. Dosage was divided between two capsules taken daily 
after breakfast with a glass of water for the duration of the study. 
Hooper et al. (1980), using experimental and control groups, 
administered 220 mg. zinc sulfate to the experimental group. 
Subjects took the capsules twice a day with meals. Crouse et al. 
(1984) administered 50 mg. zinc sulfate. Subjects were instructed 
to ingest one capsule daily midway between breakfast and lunch. 
Goodwin et al. (1985) did not adminster zinc supplements. 
Correlations for the subjects' exercise with serum HDL cholesterol 
and the self reports of supplemental zinc use during the study were 
calculated. As an intervention study, the investigators identified 23 
subjects who were taking >15 mg a day zinc and who had no change 
in supplemental intake in six months. These subjects agreed to stop 
taking zinc supplements or to substitute a multivitamin not 
containing zinc for an eight week period. 
The timing of zinc supplementation varied among the five 
studies. There is little, if any, available data on whether the timing 
of supplement use, use with or without meals, or the number of 
supplements taken per day influences diurnal variation in plasma 
zinc or copper levels or blood lipids. Nevertheless, drug studies 
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indicate that dosage use is an important factor that could be a 
confounding variable in interpreting results between studies. 
Supplementation Monitoring 
Hooper et al. (1980) stated their subjects received a zinc 
sulfate capsule twice a day with meals. They implied that the 
investigators distributed the supplements each day. Black et al. 
(1988) had subjects take the capsules without monitoring. Crouse 
et al. (1984) had subjects maintain a daily record of capsule 
ingestion. On an average, the subjects missed two capsules 
throughout the entire eight week study. Freeland-Graves et al. 
(1980), like Hooper et al. (1980), administered supplements directly 
to the subjects. Goodwin et al. (1985), as mentioned elsewhere, did 
not adminster zinc but observed HDL-C differences between subjects 
taking zinc supplements and subjects not taking zinc supplements. 
Study Design 
Hooper et al. (1980) obtained informed consent from subjects, 
asked them not to alter alcohol ingestion, exercise, smoking and 
diet, and they obtained three fasting baseline lipid profiles. Twelve 
of the 20 subjects received zinc sulfate, and eight subjects received 
a placebo. Fasting lipid levels were determined on a weekly basis 
and continued two weeks after the zinc supplementation stopped. A 
final lipid determination was done 16 weeks after the study began. 
Freeland-Graves et al. (1980) randomly divided participants, in 
a double blind design, into four groups of eight subjects each. The 
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subjects received either 0, 15, 50 or 100 mg zinc supplements. 
Blood samples were taken at two week intervals over a 60 day 
period. 
Crouse et al. (1984) divided subjects into endurance trained and 
sedentary categories. Subjects were matched for age and randomly 
assigned to either treatment or placebo group. Ten-hour post 
absorptive blood samples were obtained from each subject on three 
separate days, and the zinc and placebo capsules were dispensed 
using a double blind procedure. Blood samples were collected 
biweekly after an overnight fast throughout the eight week 
treatment period. 
Using self reported information, Goodwin et al. (1985) divided 
subjects into those who exercised and those who did not exercise; 
and into those subjects who took zinc supplements and those who 
did not. Correlation coefficients were then calculated between the 
level of exercise, zinc supplement use and serum HDL cholesterol. 
As a separate part of the study, 28 subjects who took supplemental 
zinc >15mg/dL were identified. Of these, 23 subjects who had no 
change in supplemental zinc intake in the previous six months agreed 
to stop zinc supplements or to substitute a multivitamin with 
mineral preparation not containing zinc. The subjects were free of 
zinc supplementation for eight weeks. 
Black et al. (1988) randomly divided subjects by double blind 
design into three treatment groups. Subjects in each group received 
either 50 mg zinc, 75 mg zinc or a placebo tablet. Blood and urine 
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samples and diet records were collected biweekly. Blood was drawn 
biweekly after 12 hour fasting. 
Diet 
Hooper et al. (1980) and Crouse et al. (1984) controlled for diet 
solely by asking subjects not to alter their usual diet. Goodwin et 
al. (1985), however, conducted an elaborate procedure. The dietary 
intake of zinc was assessed from a single three day food record 
during three successive weekdays. At the end of the three day food 
recording period, a dietitian visited the subjects' homes to check the 
completeness of the records. If vitamin and/or mineral supplements 
were used by the subject, the brand name, contents, and amounts of 
each nutrient were recorded. All food records were coded and then 
analyzed by computer for nutrient composition using a nutrient data 
base obtained from Case Western Reserve University, Cleveland, 
Ohio. Total zinc intake was calculated as the average daily intake 
from the three day food record plus the zinc contained in any 
supplemental mineral preparations each subject was taking. 
Freeland-Graves (1980) also used a dietary record. The three 
day records were "kept throughout the experiment", but the 
investigators did not mention the frequency of the record. 
Nevertheless, nutrient intakes were calculated from a computer 
assisted program of USDA food composition tables. Mean dietary 
zinc was then added to the amount of supplemental zinc each 
participant received during the study. This amount was then divided 
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by the mean dietary copper. The mean Zn/Cu ratios for the four 
treatment groups as calculated were 3 ±2, 13 ± 4X 21 ± 8, 64 ±_23. 
Black et al. (1988) collected diet history for each subject during 
the initial interview. Three day diet records were obtained 
biweekly, and data was coded and analyzed for nutrients by a 
Nutritionist III computer program. 
Blood Sampling 
All studies used fasting samples and similar blood collection 
procedures. Freeland-Graves et al. (1980) had fasting subjects 
donate 12 ml samples of blood on Tuesday mornings from 7-9 a.m. at 
two week intervals. Venous blood was withdrawn from the forearm 
via disposable syringes equipped with 21 gauge stainless steel 
needles and tranferred to acid washed, polypropylene test tubes. 
Whole blood was allowed to clot at room temperature for 20 minutes 
and frozen until subsequent analysis. Heparinized plasma was 
obtained via centrifugation at 3500 rpm for 10 minutes in a clinical 
centrifuge. Plasma was either diluted with deionized water for 
mineral analysis or immediately analyzed for lipid content. 
Crouse et al. (1984) collected all fasting blood samples in trace 
mineral-free vacuum-collecting tubes, and the plasma was stored at 
-60° C. At the conclusion of the study, the plasma was thawed and 
analyzed for total cholesterol, HDL cholesterol and triglycerides by 
techniques specified by Livin and Zak (1964), Lopes-Virella, Stone, 
Ellis and Colwell (1977) and Kessler and Lederer (1965), 
respectively. 
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Goodwin et al. (1985) measured fasting lipid profile at the time 
of the initial instruction in completing food records. Serum was 
analyzed for cholesterol, triglycerides and HDL cholesterol as 
specified by Livin et al. (1964), Kessler et al. (1965) and National 
Heart, Lung and Blood Institute (1975). 
Hooper et al. (1980) obtained three fasting baseline lipid 
profiles prior to zinc capsule administration. Fasting lipid levels 
were determined on a weekly basis and continued two weeks after 
zinc supplementation ended. 
A final lipid determination was done 16 weeks after the study 
began. Fasting serum was analyzed for cholesterol (Livin et al., 
1964), triglyceride (Kessler et al., 1965) and high density 
lipoprotein cholesterol (Lopes-Virella et al., 1977). 
Black et al. (1988) drew a morning 12 hour fasting blood sample 
at baseline and biweekly intervals by venipuncture. The blood was 
allowed to clot for 60 minutes and centrifuged at 400 x g for 20 
minutes. Serum was removed, placed in acid washed tubes and 
either frozen for mineral analysis or immediately separated into 
lipoprotein fractions. 
In summary, all investigators basically used the same 
methodology to measure total cholesterol and HDL-C. According to 
the National Heart, Lung and Blood Institute (1975) data, plasma 
which was used by Crouse (1984) produces higher values than serum 
(Goodwin; 1985). 
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Activitv/Exercise Assessment 
Hooper et al. (1980), Crouse et al. (1984), Black et al (1988) and 
Freeland-Graves et al. (1980) had no exercise component and, thus, 
did no exercise assessment. Goodwin et al. (1985) used an exercise 
history modified from Cassel (1971). This history provides a score 
in arbitrary units, based on response to weighted questions about 
level of physical activity. In general, scores over 20 indicate that 
the subject is getting some regular form of vigorous aerobic 
physical exercise, such as jogging or playing tennis. Scores of 10 or 
20 are obtained in subjects who regularly (at least three times a 
week) engage in walking, playing golf or a similar activity. Scores 
less than 5 indicate a sedentary individual performing little more 
than house work. Goodwin et al. (1985) found a weak positive 
correlation between the level of exercise and serum HDL cholesterol 
in the 180 subjects not taking supplemental zinc (r=0.26; p=0.005) 
but not for those subjects taking supplemental zinc (r=-0.18; 
p=0.14). 
Body Fat Measures 
Goodwin et al. (1985) controlled for body mass index, but they 
did not elaborate on how body mass index affected subjects' 
cholesterol or zinc status. Freeland-Graves et al. (1980) and Hooper 
et al. (1980) apparently did not consider body fat in their research. 
Crouse et al. (1984) included weight and body mass index but didn't 
provide any evidence of using these variables in interpreting their 
results. Black et al. (1988) stated only that their selected subjects 
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were not more than 20 percent above or 10 percent below their ideal 
body weight as determined by the 1983 Metropolitan Life Insurance 
Tables. 
Statistical Analysis 
Goodwin et al. (1985) used SAS for statistical analysis and 
conducted correlation, partial correlation and multiple regression 
analysis. The regression model expressed HDL-cholesterol as a 
linear combination of physical exercise level, total daily zinc intake 
and the product of physical exercise level and total zinc intake. A 
two tailed paired t test was used to compare values before and after 
stopping zinc supplements. 
Crouse et al. (1984) analyzed total cholesterol, triglycerides, 
LDL-cholesterol, HDL cholesterol and zinc data by multiple profile 
analysis. The mean of the pretreatment measures was considered 
the baseline value for each dependent variable. To set the Type 1 
error at an acceptable level, the Bonferroni procedure was used. 
This approach adjusts the critical value of the individual tests to 
yield individual Type 1 errors that sum up to the desired total 
experimental error. This procedure does not require that the 
significance criteria for the individual tests be equivalent. They 
may, in fact, be lower for the hypotheses of greatest theoretical or 
practical importance. 
Freeland-Graves (1980) used a computerized program, 
STATPACK (Clark and Hunt, 1977), to isolate significant differences 
in initial, continuous and final concentrations of constitutents in 
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the blood and diet by two-way analysis of variance. Comparisons of 
means of grouped data, paired t-tests and simple partial regression 
analysis were measured for the assessment parameters using the 
computerized program, OMNITAB (Hogben, Peavy, Varner, 1971). 
Black et al. (1988) used a computerized one way analysis of 
variance with repeated measures program to analyze data. When 
initial mean baseline values differed between treatments, data were 
covariate adjusted for baseline values with levels of zinc 
supplementation and time. 
Summary of Study Results 
Freeland-Graves et al. (1980) found no uniform response of 
plasma cholesterol concentrations to altered dietary Zn/Cu ratios. 
Only subjects with the highest Zn/Cu ratio showed changes in 
plasma HDL-cholesterol that followed a decline and subsequent 
increase of plasma cholesterol. As stated previously, the Zn/Cu 
ratio that was assigned to each group was calculated from the mean 
dietary zinc added to the supplemental zinc and divided by the mean 
dietary copper. Dietary means of zinc and copper were based on 24 
values for each subject obtained from three day dietary records kept 
at weekly intervals over the eight week study. 
Hooper et al. (1980) observed decreased HDL-cholesterol 
concentrations following zinc administration. After four weeks of 
zinc (220 mg zinc sulfate/80 mg elemental zinc) administration, 
HDL-cholesterol concentrations decreased significantly (mean 
decline from baseline, 6 mg/dL; p=0.002). By the seventh week, HDL-
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cholesterol levels decreased 25 percent from baseline (from 40.5 to 
30.1 mg/dL; p=0.0001). Sixteen weeks after study initiation (11 
weeks after zinc administration stopped ) HDL-cholesterol values 
returned to near-baseline values. 
Goodwin et al. (1985) found zinc supplementation abolished the 
beneficial effects of exercise on increasing serum HDL-cholesterol. 
In those 184 subjects not taking supplemental zinc, the partial 
coefficient of correlation between exercise and HDL cholesterol was 
0.26 (p=0.005), while the same correlation for those on zinc 
supplements was -0.18 (p=0.14). The relationship between total 
zinc intake, physical exercise and HDL-cholesterol showed 
significant positive interaction. This significant interaction 
suggested that zinc intake influences the effect of physical activity 
on HDL-cholesterol. HDL-cholesterol was positively associated with 
activity level only for those subjects in the lowest zinc intake 
group. 
A statistically significant increase in HDL cholesterol level (2.0 
mg/dl, p=0.04) occurred after cessation of zinc supplements. Among 
subjects taking zinc supplements, the physical activity and change 
in HDL-cholesterol were positively associated (after stopping 
supplementation). 
There appeared to be a relationship between the level of 
physical activity and change in HDL-cholesterol after stopping zinc 
(r=0.41, p=0.05). Those subjects with low physical activity ratings 
had very small increases or even decreases in HDL-cholesterol after 
stopping zinc. Subjects with higher physical activity scores had 
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larger increases in HDL after stopping zinc. Goodwin et al. (1985) 
went on to state, however, that, while statistically significant, this 
relationship was weak and could almost entirely be explained by two 
subjects at the low end of the scale and one subject at the upper end 
of the scale. 
Both Hooper et al. (1980) and Goodwin et al (1985) observed 
decreased HDL cholesterol concentration in the presence of 
increased zinc supplementation. Because HDL is apparently the 
lipoprotein most predictive of coronary artery disease (Castelli, 
Doyle & Gordon, 1977), a sustained fall in HDL concentration 
associated with zinc administration might increase the risk of 
coronary artery disease. These studies seem to indicate that zinc 
may be atherogenic in man — not because zinc raises serum 
cholesterol levels in rats, but because it is associated with 
lowering HDL-cholesterol in man. 
Black et al. (1988) found serum total cholesterol, low density 
lipoprotein cholesterol (LDL), very low density lipoprotein 
cholesterol (VLDL) and triglycerides unaffected by zinc 
supplementation. HDL cholesterol in subjects assigned to the 75 mg 
zinc group were significantly lower at weeks 6 (53 mg%) and 12 (54 
mg%) than those for the placebo group. HDL cholesterol in subjects 
assigned to the 75 mg zinc group were lower at weeks 6 (53 mg%), 8 
(51 mg%) and 12 (54 mg%) than at baseline. Subjects assigned to the 
50 mg zinc group had lower serum HDL levels at week 12 (55 mg%) 
than did the placebo group (63 mg%). Subjects assigned to the 50 mg 
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zinc group had lower serum HDL at week 12 (55 mg%) than at 
baseline (59 mg%). 
The previous studies included a wide range of zinc 
supplementation. The range varied from 50 mg (Black et al., 1988) 
to 220 mg (Hooper et al., 1980). The primary question involved in 
the proposed research was whether low level zinc supplementation 
(15 mg) maintained/enhanced zinc stores without increasing total 
cholesterol or decreasing HDL cholesterol. Previous studies have 
included relatively high levels of supplementation: 220 mg (Hooper 
et al., 1980), 50 mg (Crouse et al., 1984) and 15 to 100 mg 
(Freeland-Graves et al., 1980). The study period for Freeland-Graves 
et al. (1980), Hooper et al. (1980) and Crouse et al. (1984) was 60 
days, five weeks and eight weeks, respectively. The dissertation 
research period was 12 weeks long, and the level of zinc 
supplementation was in the lowest range of the doses used in these 
studies. 
The previous studies assessed total cholesterol and HDL 
cholesterol (Crouse et al., 1984; Goodwin et al, 1985; Hooper et al., 
1980; Freeland-Graves et al., 1980). The present study, in addition 
to total cholesterol and HDL cholesterol, included the measurement 
of HDL2 cholesterol and HDL3 cholesterol. 
Previous studies monitored supplementation by dispensing 
capsules daily (Hooper et al., 1980; Freeland-Graves et al., 1980) or 
having subjects maintain a daily record of capsule ingestion (Crouse 
et al., 1984). In this disseration research, subject compliance was 
monitored by the following procedure: an extra two capsules were 
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included in a 12 weeks' supply of capsules dispensed to subjects. 
Compliance was measured by whether the allotted number of extra 
capsules were in each subject's container when containers were 
returned at the end of the study. Also, subjects completed a 
calendar given them at the beginning of the study. Each day was 
checked when the subject ingested the zinc or placebo capsule. 
Compliance was encouraged during weekly RESHAPE meetings and 
RESHAPE exercise sessions held three times a week. 
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Table 1 
Summary of Human Studies of Zinc Supplementation on Lipid Profiles 
Principal Subjects Study Subfect Zinc Response 
Investigators Length Age Level 
Freeiand-Grave, 
Han, Friedman & 
Shorey (1980) 
32 women 60 days 18-40 
Garry, Johnson, 12 males 
Hooper & Visconti 
(1980) 
5 weeks 23-35 
0. 15, 
50, 
100 mg 
440 mg. 
Goodwin, Hunt, 
Hooper & Garry 
(1985) 
270 men & 
women 
5 years 60 yrs or >15 mg. 
older 
No uniform nor sustained 
response of plasma 
cholesterol or HDL-C 
HDL-C decreased 25% 
below baseline 40.5 
to 30.1 mg/dL. Total 
cholesterol, TG, LDL 
did not change. Zinc 
ingestion may be 
atherogenic. 
After controlling for sex, 
alcohol intake, and body 
mass, significant positive 
correlation between exercise 
and serum HDL-C in subjects 
not taking supplemental Zn. 
Zn correlated with low HDL-C. 
Crouse, Hooper 
Atterbom & 
Pappenfuss 
(1984) 
21 
endurance 
trained men 
& 23 
sedentary 
men 
8 weeks 20-55 yrs. 50 mg. Fasting plasma high. 
High density lipoprotein 
cholesterol, total cholesterol, 
low density lipoprotein cholesterol 
cholesterol and triglyceride levels did 
not change in response to zinc 
supplementation 
Black, Medeiros, 
Brunett & 
Welke 
(1988) 
30 white 
males 
12 weeks 19-29 yrs. 0,50, 
75 mg 
Serum total cholesterol not 
affected. HDL levels in 75 mg 
group significantly lower 
at weeks 6 and 12 than placebo 
group and lower at weeks 6, 8, 
12 than at baseline. Subjects 
in 50 mg group had lower serum 
HDL at week 12 than placebo group 
and lower HDL at week 12 than at 
baseline. 
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CHAPTER III 
METHODOLOGY 
Subject? 
Subjects were selected from the 1987-88 fall and spring 
replications of the RESHAPE program. RESHAPE is a 12-week 
program which consists of 12 lifestyle management workshops and 
36 activity sessions. The activity sessions last 20 to 60 minutes 
and are conducted on Monday, Wednesday and Friday of each week. 
The initial activity period is 20 minutes which is increased by five 
minutes weekly until week nine. The activity period is maintained 
at 60 minutes for weeks 9-12. Almost 500 subjects have been 
screened for participation in this program which was first 
implemented in 1982. 
After giving informed consent, volunteers were matched 
according to their total cholesterol:HDL-C ratio by gender and 
randomly assigned to two groups, either experimental (E) or control 
(C). All subjects were questioned to determine whether they were 
taking any medications. Females were questioned to determine if 
they were non-gravid and not using oral contraceptive agents. 
Subjects on medication or oral contraceptives were dropped from 
participation. Initial parameters of zinc, copper and hematocrit 
were determined by blood analysis. All lipid variables were 
determined and diet was measured using a three day food record as 
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described in a later section. Blood pressure was measured after 
sitting for at least five minutes. 
Experimental Design 
After a fasting baseline lipid profile was obtained (week 0), 
subjects received 84 capsules and were instructed to take one per 
day for 12 weeks. Capsules were distributed in a double blind 
fashion. E subjects received capsules containing 15 mg. of zinc 
sulfate, while C subjects received a placebo. Two methods were 
used to check patient compliance. The first method was based on 
counting the number of capsules the subjects returned. An extra two 
capsules were placed in each subject's capsule container. The 
subjects were asked to return all unused capsules. The second 
method was a compliance chart on which subjects checked each day 
they took their capsules. Fasting lipid, zinc and copper levels were 
determined at both weeks 0 and 12. 
As part of the RESHAPE program, subjects attended 12 lifestyle 
management workshops and 36 activity sessions. The lifestyle 
management workshops lasted one and a half hours each and were 
held on Wednesday evenings each week. Activity sessions consisted 
of 5-10 minute warm-ups, 20-60 minutes of continuous activity 
(walking and/or jogging) at 65-75 percent of maximum heart rate 
(determined by the Karvonen formula), and a 5-10 minute cool-down. 
The initial activity period was 20 minutes which increased by five 
minutes weekly until week nine. The activity period was maintained 
at 60 minutes for weeks 9-12. 
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Dietary Intake 
Prior to zinc supplementation, the dietary intake of zinc was 
assessed from a single three day food record collected during two 
successive weekdays and one weekend day (Freeland-Graves et al., 
1980; Goodwin et al., 1985). The subjects were instructed on how to 
keep an accurate three day food record. All food items and portions 
were recorded on standard forms for each day. Each volunteer was 
asked to include food brand names, methods of food preparation and 
recipes for any mixed dish eaten during the period. At the end of the 
three day recording period, each food record was evaluated for 
completeness and accuracy. Participants were asked to provide 
additional information about any unclear descriptions. If the 
subject used vitamin and/or mineral supplements, the brand name, 
contents and amount of each nutrient was recorded. All food records 
were coded and then analyzed by computer for nutrient composition. 
All food records were coded by food item and the amount consumed. 
A computerized nutrient data base, Nutranal 3.1 Software Package 
(1980), was used to calculate the nutrient content of each subject's 
three day food record. 
Bazzarre and Myers (1978) have noted that reliability tests for 
any dietary method suffer from a number of limitations pertaining 
primarily to the inability to establish identical conditions in 
subsequent tests. Obfuscating factors include within-individual and 
methodological variability. Bazzarre and Yuhas (1983) have stated 
that the 3-day food record and diet history are more reliable 
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measures of nutrient intake than the 24 hour recall. They also found 
that the 3-day food record and diet history correlated better with 
fasting total cholesterol than did the 24 hour recall. On the basis of 
these findings, the 3-day food record was recommended for 
investigations measuring actual food intake. 
Fitness Evaluation 
Subjects' fitness was determined by the time they took to walk 
a mile. Mile walk times were taken at both the beginning and end of 
the program (Cooper, 1977). 
Collection and Preparation of Samples 
A fasting lipid profile was obtained at the time of the initial 
instruction in completing food records. Fasting subjects donated 12 
ml samples of blood on a single day (e.g., Tuesday) during the 
morning (7-9 a.m.) at weeks 0 and 12. Venous blood was withdrawn 
from the forearm via trace mineral free Vacutainers™ with a 21 
gauge stainless steel needle. Whole blood was allowed to clot at 
room temperature for 20 minutes and the serum was frozen until 
subsequent analysis. Heparinized plasma was obtained via 
centrifugation at 3500 rpm for 10 minutes in a clinical centrifuge. 
Plasma was frozen and later analyzed for lipid content. Serum 
samples (weeks 0 and 12) were stored at -70° C, and samples for all 
subjects were assayed in duplicate in the same run under coded 
designation. Serum was analyzed for concentrations of total 
cholesterol and HDL (Sigma Diagnostics, 1986). Duplicate samples 
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were re-analyzed if the percent difference was greater than two 
percent. 
Body Fat Measures 
Subjects were also assessed using Body Mass Index and skinfold 
measurements. Body Mass Index (BMI) or Quetelet Index is derived by 
the following: 
weight fka) 
height (m)2 
The BMI is compared to values in the following table: 
Minimum body mass index in obesity 
Frame Size Men Women 
small 25.4 24.7 
medium 27.0 27.0 
large 29.9 29.9 
Source: Adapted from Zeman, P.J.: Clinical Nutrition and Dietetics. 
Lexington, MA: D.C. Heath and Co., 1983. 
Values of obesity greater than the table values are indicative of 
obesity. BMI may not adequately reflect variations in body fat 
(American Dietetic Association, 1986). Critics (Gam, Leonard and 
Hawthorne, 1986) have charged that, since stature, i.e., standing 
height, is one component of BMI, BMI may be stature dependent over 
part of the age range. For example, in the first National Health and 
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Nutrition Examination Survey (NHANES I) correlations between 
stature and BMI approximate 0.30 for children, shift during 
adolescence and become negative in adult years. In addition, the use 
of stature as a divisor suggests that BMI may be affected by relative 
leg length or relative sitting height. NHANES data also indicate that 
children, adolescents or adults with short legs for their height have 
higher BMI values, which indicates the extent to which BMI is a 
measure of body build or body proportions. Finally, the use of weight 
as the numerator suggests that the BMI, like weight itself, may 
reflect both lean tissue and fat tissue to a comparable degree. The 
latter issue is the main limitation of the BMI. One cannot 
distinguish excess weight due to excess body mass from excess 
weight due to excess body fat. 
The measurement of skinfolds at various appropriate body sites 
should reflect the body's storage fat (Katch and McArdle, 1983). 
Skinfold measurements can be used to assess an individual's change 
in percent body fat in weight reduction programs, and before and 
after physical conditioning. Advantages of the skinfold 
measurement technique are that little equipment is necessary and 
the procedure can be performed quickly with simple interpretation. 
If measurements are taken correctly, and the data obtained are 
applied to the appropriate equation based on age and sex, the 
percentage body fat determined from the skinfolds correlates well 
with results using hydrostatic weighing (Pollock, M.L. and Jackson, 
A.S., 1984). The main limitation of using skinfolds is that internal 
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body fat stores are estimated on the basis of measures of 
superficial body fat (Blair, Haskell, Ho, 1985). 
Mineral Analysis 
Zinc and copper concentrations in blood were analyzed by atomic 
absorption spectrophotometry. Samples were diluted with deionized 
water to appropriate concentrations. Blank solutions were prepared 
in a similar manner to reveal any detectable mineral contamination 
from the procedure. A Perkin-Elmer Model 290-B atomic absorption 
spectrophotometer equipped with a three slot burner head, a single 
element hollow cathode ray lamp and an automatic readout were 
used to read mineral concentrations (Freeland-Graves et al., 1980). 
Cholesterol and HDL Cholesterol Analysis 
The procedure involved cholesterol measurement as published by 
Allain, Poon, Chan, Richmond, and Fu (1974). The procedure 
generated oxidation products by cholesterol oxidase following 
cholesterol ester hydrolysis by cholesterol esterase. The use of 
these enzymes was coupled with the p-hydroxybenzenesulfonate and 
4-aminoantipyrine chromogenic system. The reactions employed 
were as follows: 
1. Cholesterol Esters Cholesterol Esterase > Cholesterol + Fatty acids 
2. Cholesterol + O2 Cholesterol Oxidase > Cholest-4-en-3-one + H2O2 
3. 2H2O2 + 4-Aminoantipyrine + p-Hydroxybenzene-sulfonate Peroxi<Jase> 
Quinoneimine Dye + 4H2O 
40 
In the last step, hydrogen peroxide reacted with 4-
aminoantipyrine with p-hydroxybenzenesulfonate in the presence of 
peroxidase to yield a quinoneimine dye, which had a maximum 
absorbance at 500 nm. The amount of color produced was directly 
proportional to the concentration of total cholesterol in the sample. 
Cholesterol and other lipids were present in the form of 
lipoproteins. Diagnostic significance has been attached to the 
cholesterol concentrations associated with high density lipoproteins 
(HDL), which appeared inversely related to the incidence of coronary 
artery disease (Castelli et al., 1977). The procedure for 
determination of HDL cholesterol was based on selective 
precipitation of low density lipoproteins (Lopes-Virella, Stone, 
Ellis, & Colwell, 1977). HDL-cholesterol was determined 
enzymatically by the method described by Allain et al. (1974). HDL2 
and HDL3 were determined by a simple precipitation procedure as 
described by Lewis et al. (1982). 
Statistical Analysis 
Statistical analysis was accomplished with the aid of SAS 
(Statistical Analysis System), version 79.6. Because the data were 
not normally distributed for several variables for males, 
nonparametric statistical tests were used to test all hypotheses. 
To compare medians between each control and experimental group at 
week 0 and week 12, the paired comparisons t-test was used for all 
variables. The Wilcoxon test using median difference scores was 
used to determine if the changes from week 0 to week 12 were 
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significantly different between the control (C) and experimental (E) 
groups. Spearman correlation was used to measure associations 
between zinc status and specific variables. A significance criterion 
of p<0.05 was used for all tests. 
42 
CHAPTER IV 
RESULTS 
The results of this research are summarized in Tables 2 through 
18 and Appendices A-1 through A-15. In reviewing the preliminary 
results, the data were not normally distributed for several variables 
for males. To be consistent, nonparametric statistical tests were 
used to test all hypotheses. To compare medians between each 
control and experimental group at week 0 and week 12, the paired 
comparisons t-test was used for all variables. The Wilcoxon test 
using median difference scores was used to determine if the changes 
from week 0 to week 12 were significantly different between the 
control (C) and experimental (E) groups. Because nonparametric 
statistics were used, median values are presented in the tables. All 
Wilcoxon scores and related statistics for comparing medians 
between groups at each week are reported in the appendices. 
Participation 
Forty-seven subjects were recruited. There were five 
experimental male subjects, seven control male subjects, 17 
experimental female subjects and 18 control female subjects. 
Dropouts occurred in each group. Dropouts included two E and two C 
male subjects, five E and nine C female subjects. Twenty-nine 
subjects remained until the end of the study. Approximately 37 
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percent of the original population was not available for final data 
analysis. The primary reasons for dropping out were not evaluated. In 
the final group, only four subjects returned dietary data at the end 
of the program, and eleven subjects did not participate in final 
walk/run evaluation. 
Because of the high percentage of dropouts in each subgroup 
from week 0 to week 12, the descriptive statistics for the entire 
sample are presented in the appropriate appendices. The data 
presented in the tables where comparisons between week 0 and 
week 12 are made represent data for subjects available from both 
data collection periods. 
The format for reporting data includes an evaluation of 
descriptive traits of E and C groups, both male and female, i.e., age, 
height, weight. This section is followed by data for skinfold 
measures, percent body fat, body mass index and the prevalence of 
obesity among the groups. The data for the lipid profiles of the 
sample and serum and dietary zinc and copper for the sample are 
reported. Finally, the results for the evaluation of the presence of 
associations between selected variables are presented. The sample 
size for each subgroup varies for fitness because not all subjects 
completed the fitness test. 
In the following text, results are reported with an accompanying 
probability statistic only if the results are significant, i.e., p<_ 0.05. 
In all other cases, no probability statistic will appear. Probability 
levels are reported in appropriate tables and appendices. 
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Subject Monitoring 
As stated previously, two methods were used to check patient 
compliance. The first method was based on counting the number of 
capsules the subjects returned. An extra two capsules were placed 
in each subject's capsule container. The subjects were asked to 
return all unused capsules. The second method was a compliance 
chart on which subjects checked each day they took their capsules. 
Of the 16 subjects returning the calendar, each took the capsules 
every day. Ninety percent of the subjects returned their capsule 
containers. Each of the returned containers contained two capsules. 
Descriptive Traits of Sample 
Age (E:43 ±12 years vs. C:41 ±. 13 years ), height (E:69 ±.4 
inches vs. C:69 ± 3 inches ) and initial weight (E:212 ± 79 pounds vs. 
C:233 ± 47 pounds) were similar for E and C males (Table 2). Age 
(E:40 ± 11 years vs. C:39 ± 13 years), height (E:66 ± 3 inches vs. C:65 
±. 2 inches) and initial weight (E:166 ±. 27 pounds vs. C:161 ±. 33 
pounds) were not significantly different for E and C females (Table 
2). 
Measures of Obesity 
Final weight (E:208 ± 28 pounds vs. C:230 ± 56 pounds), initial 
skinfold (E:79 ± 31 mm vs. C:88 ± 20 mm), final skinfold (E:75 ± 26 
mm vs. C:77 ± 29 mm), initial percent body fat (E:29 ±. 10 vs. C:32 ± 
4), final percent body fat (E:31 ± 9 vs. C:32 ± 3), initial body mass 
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Table 2 
Aae. Height, and Weight of Studv Population of Week 0 (Medians and 
Standard Deviations! 
Males Females 
Groups Zinc Placebo Zinc Placebo 
(n)  (3)  (5)  (12)  (9)  
Age 
(years)  
43 ± 12 41 ± 13 40 ± 11 39 ± 13 
Height 
(inches) 
69 ± 4 69 ± 3 66 ± 3 65 ± 2 
Weight 
( lbs)  
212 ± 79 233 ± 47 166 +27 161 ± 33 
index (BMI) (E:31 ± 6 vs. C:32 ±  7 ) ,  and final BMI (E:27 ± 5 vs. C:29 ± 
7) were not significantly different between E and C males (Table 3). 
Final weight (E:156 ±. 19 pounds vs. C:151 ±. 35 pounds), initial 
skinfold (E:111 ± 29 mm vs. C:93 ± 41 mm), final skinfold (E:91 ± 29 
mm vs. C:85 ± 35 mm), initial percent body fat (E:39 ± 4 vs. C:37 ± 6), 
final percent body fat (E:36 ± 6 vs. C:35 ± 6), initial body mass index 
(BMI) (E:26 ±. 4 vs. C:27 ± 8), and final BMI (E:24 ± 4 vs. C:26 ± 
8)(Table 3) were not significantly different between E and C 
females. 
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Table 3 
Descriptive Statistics of Study Population at Weeks 0 and 12 
(Medians and Standard Deviations) 
Males Females 
Groups Zinc Placebo Zinc Placebo 
(n)  (3)  (5)  (12)  (9)  
In i t ia l  
Weight 
(Lbs.) 
210 ± 38 245 ± 52 166 ± 22 159 ± 41 
Final 
Weight 
(Lbs. )  
208 ± 28 230 ± 56 156 ± 19 151 ± 35 
In i t ia l  
BMI  31 ± 6 32 ± 7 26 ± 4 27 ± 8 
Final 
BMI  27 ± 5 29 ± 7 24 ± 4 28 ± 8 
In i t ia l  
Skinfold 
(mm) 
79 ± 31 88 ± 20 111 ± 29 93 ± 41 
Final 
Skinfold 
(mm) 
75± 26 77 ± 29 91 ± 29 85 ± 35 
In i t ia l  
Percent 
Body Fat 29 ± 10 32 ± 4 39 ± 4 37 ± 6 
Final 
Percent 
Body Fat 31 ± 9 32 ± 3 36 ± 6 35 ± 6 
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Body mass index was divided into three categories: normal, 
overweight and obese (Table 4). These categories were defined as 
follows: 
normal weight < 25 kg-m-2 
overweight = 25-29.9 kg-nrr2 
obesity > 30 kg-m-2 
According to these criteria, 43 percent of women and 25 percent 
of men were initially classified as normal weight/fat (Table 4). 
Sixty-three percent of men and 23 percent of women were classified 
as obese. 
From week 0 to week 12, the percentage of males classified as 
normal weight decreased from 25 percent at week 0 to 12.5 percent 
at week 12; the percentage of males classified as overweight 
increased from 12.5 percent to 50 percent; and the percentage of 
males classified as obese decreased from 62.5 percent to 37.5 
percent (Table 4). The percentage of females classified as normal 
weight increased from 42.9 percent at week 0 to 66.7 percent at 
week 12; the percentage of females classified as overweight 
decreased from 33.3 percent to 19.0 percent; and the percentage of 
females classified as obese decreased from 23.8 percent to 14.3 
percent (Table 4). 
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Table 4 
Incidence <?f Exce?? AdlppgHy amgng Initial Stvdy Popflatlpn pt Week Q 
Group Males 
n (%) 
Females 
n (%) 
B Ml 
Week 0 Week 12 Week 0 Week 12 
normal 
overweight 
obese 
2 (25.0) 
1 (12.5) 
5 (62.5) 
1 (12.5) 
4 (50.0) 
3 (37.5) 
9 (42.9) 14 (66.7) 
7 .(33.3) 4 (19.0) 
5 (23.8) 3 (14.3) 
% Body Fat 
normal 1 (12.5) 1 (4.8) 
overweight 1 (12.5) 6 (75.0) 1 (4.7) 2 (9.5) 
obese 6 (75.0) 2 (25.0) 20 (95.0) 18 (85.7) 
- 2  
1. BMI= weight Overweight Is defined as 25-29.9 kg-m weight 
height (mf *or 0l,es'ty 's defined as greater than or 
equal to 30 kg-m weight for height. 
2. Percent body fat estimated from sum of four skinfolds using the equation 
of Durnln and Womersley (1973). Overweight defined as 20-28 percent 
for males and 22-30 percent for females. Obesity Is greater than 28 
percent for males and greater than 30 percent for females. 
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Percent body fat was estimated from the sum of four skinfolds 
using the equation of Durnin and Womersley (1973). The categories 
were defined as follows: 
The percentage of males classified as normal decreased from 
12.5 percent to 0 percent; the percentage of males classified as 
overweight increased from 12.5 percent to 75 percent; and the 
percentage of males classified as obese decreased from 75 percent 
to 25 percent. The percentage of females classified as normal 
increased from 0 percent to 4.8 percent; the percentage of females 
classified as overweight increased from 4.7 percent to 9.5 percent; 
and the percentage of females classified as obese decreased from 95 
percent to 85.7 percent (Table 4). 
Body weight decreased for males (E: -5.6 ±11.7 pounds vs. C; -
6.2 ±. 2.1 pounds) and females (-8.6 ±. 3.4 pounds vs. -6.5 ±. 1.1 
pounds), but not significantly (Table 5). Similarly, body fat 
decreased among males (E:-1.1 ± 0.8 percent vs. C:-0.5 ± 3.3 percent) 
and E females (-1.4 ± 5.4 percent) but, again, not significantly. The 
percent body fat among C females decreased significantly (-1.1 ± 1.5 
percent;p<0.006). 
% Body Fat 
Normal 
Overweight/fat 
Obese 
Males 
<20 percent 
20-28 percent 
>28 percent 
Females 
<22 percent 
22-30 percent 
>30 percent 
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Table 5 
Paired Comparions T-Test of Body Weight and Body Fat 
Mean Differencs Scores and Standard Deviations 
Variables Males Females 
Zinc Placebo Zinc Placebo 
(n)  (3)  (5)  (12)  (9)  
Body 
Weight 
Difference 
( lb )  
(Initial - Final) -5.6 ±11.7 -6.2 ± 2.1 -8.6 ± 3.4 -6.5 ± 1.1 
p-va lue 0 .42 0 .36 0 .18 0 .21 
% Body 
Fat 
Difference 
(Initial - Final) -1.1 ± 0.8 -0.5 ± 3.3 -1.4 ± 5.4 -1.1 ± 1.5 
P-value QA2 gi74 0J31 0.006 
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Fitness 
There was no statistically significant difference in fitness 
level as measured by initial mile walk time between males (E: 14.8 ±. 
3.4 minutes vs. C: 15.8 ± 0.7 minutes ) nor between females (E: 16.0 ± 
2.2 minutes vs. 14.8 ±. 1.6 minutes), and there was no statistically 
significant difference in fitness level as measured by final mile 
walk time between males (E: 14.8 ± 2.9 minutes vs. C: 14.6 ±1.2 
minutes) nor between females (E: 14.4 ± 1.4 minutes vs. 14.2 ± 1.1 
minutes)(Table 6). As measured by the paired comparison t-test, 
mile walk times for neither E nor C males improved significantly 
(E:-1.70 ± 1.73 minutes vs. C: -0.45 ± 1.34 minutes). Both E and C 
females improved significantly (E:-1.23 ± 1.71 minutes; p=0.03) vs. 
(C: -1.10 ± 1.10 minutes; p=0.03) (Table 7). 
Lipid Profile of Sample 
The following research hypotheses were tested: (The numbers 
presented in parentheses are the medians and standard deviations or 
mean difference scores and standard deviations.)The data for blood 
lipids are presented in Tables 8-10. 
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Table 6 
Initial and Final Walk time of Study Population 
(Medians and Standard Devlatios) 
Groups 
(n )  
Males 
Zinc Placebo 
(3)  (5)  
Females 
Zinc Placebo 
(12)  (9)  
In i t ia l  
Walk  
Time 
(mi  n)  
Final 
Walk  
Time 
(min)  
14.8 + 3.4 15.8 ± 0.7 
14.8 + 2.9 14.6 ± 1.2 
16.0 ± 2.2 14.8 ± 1.6 
14.4 ± 1.4 14.2 ± 1.1 
Table 7 
Paired Comparisons T-Test of Fitness fMean Difference Scores 
and Standard Deviations) 
Variable Males 
Zinc Placebo 
(n) (3) (5) 
Females 
Zinc Placebo 
(12) (9) 
Difference 
Fitness -1.70 ±1.73 
(Final-Initial) 
p-value 0.40 
-0.45 ±1.34 -1.23± 1.71 -1.10±1.10 
0.49 0.03 0.03 
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Tablo 8 
Groups 
(n) 
Initial and Final TC. HDL-C and HDL.C:TC ratio of 
Study Population (Medians and Standard Deviations) 
Males 
Zinc Placebo 
(3) (5) 
Females 
Zinc Placebo 
(12) (9) 
Initial 
Total 
Cholesterol 
(mg%) 
253 ±56 220 ±41 200 ±40 225 ±27 
Final 
Total 
Cholesterol 
(mg%) 258 ±13 197 ±53 200 ±50 226 ±34 
Initial 
HDL 
Cholesterol 
(mg%) 37 ± 1 0 47 ± 8 57 ± 15 66 ±19 
Final 
HDL 
Cholesterol 
(mg%) 40 ± 1 0 57 ± 7 49 ± 17 55 ±17 
Initial 
HDL-C:TC .16 ±.06 .21 ±.06 29 ±.06 .29 ±.10 
Final 
HDL-C:TC .18 ± .06 .25 ±.16 .26 ±.10 .26 ± .09 
Table 9 
Initial and Fine! HPL2 end HDi^ of study Population fMedlans and Standard 
Pgylatlpn?) 
Groups 
(n) 
Zinc 
(3) 
Males 
Placebo 
(5) 
Zinc 
(12) 
Females 
Placebo 
0) 
Initial 
HDL 2 
Cholesterol 
(mg%) 
2 ±2 9±9 13 ±9 8 ±2 
Final 
HDL 2 
Cholesterol 
(mg%) 7 ± 1 0 15 ±9 16 ±14 15 ±8 
Initial 
HDL 
3 
Cholesterol 
(mg%) 
39_± 9 42 ±21 50 ± 13 58 ±20 
Final 
HDL 
3 
Cholesterol 
(mg%) 
39_± 0 42 ±11 33 ±14 44± 12 
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Table 10 
Paired Comparisons T-Test of Lipid Variables (Means and Standard 
Pgvlptlpns) 
Variable Males Females 
Zinc Placebo Zinc Placebo 
(n) (3) (5) (12) (9) 
Total 
Cholesterol 
Difference 
(Final-Initial) 
p-value 
-6.0 ±49.5 
0.90 
-22.6 ±23.7 
0.10 
1.5 ±42.3 
0.90 
2.6 ±31.4 
0.80 
HDL 
Difference 
(Final-Initial) 
p-value 
HDL-C:TC 
Difference 
(Final-Initial) 
p-value 
5.6 ± 2.3 
0.05 
0.02 ± 0.03 
0.37 
10.6 ±13.9 
0.17 
0.02 ± 0.16 
0.21 
-3.9 ±9.1 
0.16 
-0.01 ± 0.07 
0.40 
-8.4 ±23.2 
0.30 
0.02 ±0.13 
0.41 
HDL 
2 
Difference 
(Final-Initial) 
p-value 
5.6 ± 11.7 
0.49 
6.2± 12.6 
0.33 
2.8 ±12.4 
0.45 
7.7 ±7.7 
0.01 
HDL „ 
3 
Difference 
(Final-Initial) 
p-value 
-0.3± 9.7 
0.95 
-0.2 ±24.0 
0.98 
-13.9± 12.7 -16.3± 20.4 
0.002 0.04 
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Total Cholesterol (TC) 
tLl^E.: TC was M significantly different at week 0 versus week 
12 among experimental subjects. 
There was no significant difference in the mean difference 
scores for total cholesterol between week 0 and week 12 among 
either experimental males (-6.0 ±. 49.5 mg%) or experimental 
females (1.5 ± 42.3 mg% )(Table 10). This hypothesis was accepted. 
hLlnG.: TC was significantly different at week 0 versus week 12 
among control subjects. 
There was no significant difference in total cholesterol mean 
difference scores between week 0 and week 12 among either control 
males (-22.6 ± 23.7 mg%) or control females (2.6 ± 31.4 mg%)(Table 
10). This hypothesis was rejected. 
H-|-E:C: TC was not significantly different between experimental 
and control subjects at week 0 and 12. 
Total cholesterol was not significantly different between 
experimental and control males at either week 0 (E:253 ± 56 mg% vs. 
C: 220 ± 41 mg%) or week 12 (E: 258 ± 13 mg% vs. C:197 ± 53 mg%) 
cholesterol values (Table 8). Total cholesterol was not significantly 
different between experimental and control females at either week 
0 (E: 200 ± 40 mg% vs. C: 225 ± 27 mg%) or week 12 (E:200 ± 50 mg% 
vs.C: 226 ± 34 mg%). This hypothesis was accepted. 
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HDL-Cholesterol (HDL-C) 
HgE: HDL-C was noi significantly different at week 0 versus 
week 12 among experimental subjects. 
HDL-C increased significantly from week 0 to week 12 among 
experimental males (5.6 ± 2.3 mg%; p=0.05). No statistically 
significant difference occurred, however, for experimental females 
(-3.9 ± 9.1 mg%)(Table 10). This hypothesis was rejected for males 
and accepted for females. 
H2£.; HDL-C was significantly different at week 0 versus week 
12 among control subjects. 
HDL-C was not significantly different between week 0 and week 
12 among either control males (10.6 ± 13.9 mg%) or control females 
(-8.4 ± 23.2 mg%)(Table 10). This hypothesis was rejected for both 
males and females. 
H2~E:C:  HDL-C was  no t  s ign i f i can t l y  d i f f e ren t  be tween  
experimental and control subjects at week 0 and 12. 
Total HDL-C was not significantly different between 
experimental and control males at week 0 (E:37 ± 10 mg% vs. C:47 ± 
8 mg%) or week 12 (E:40 ± 10 mg% vs. C:57 ± 7 mg%)(Table 8). HDL-C 
was not significantly different between experimental and control 
females at week 0 (E:57 ±15 mg% vs. C:66 ±19 mg%) or week 12 
(E:49 ± 17 mg% vs. C:55 ± 17mg%). This hypothesis was accepted for 
males and females. 
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HDL Cholesterol:Total Cholesterol mDL-C:TC) 
H3-E :  The  HDL-C:TC ra t io  was  no t  significantly different at 
week 0 versus week 12 among experimental subjects. 
The HDL-C:TC ratio was not significantly different between 
week 0 and week 12 among either experimental males (0.02 ± 0.03) 
or experimental females (-0.01 ± 0.07)(Table 10). This hypothesis 
was accepted for males and females. 
H3i£.: The HDL-C:TC ratio was significantly different at week 0 
versus week 12 among control subjects. 
The HDL-C:TC ratio was not significantly different between 
week 0 and week 12 among either control males (0.02 ±. 0.16) or 
control females (0.02 ±_ 0.13)(Table 10). This hypothesis was 
rejected for males and females. 
H3-E :C :  The  HDL-C:TC ra t io  was  no t  s ign i f i can t l y  d i f f e ren t  
between experimental and control subjects at week 0 and 12. 
The HDL-C:TC ratio was not significantly different between 
experimental and control males for week 0 (E:0.16 ± 0.06 vs. C:0.21 ± 
0.06) or week 12 (E: 0.18 ± 0.06 vs. C: 0.25 ± 0.16 )(Table 8). The HDL 
cholesterol: total cholesterol ratio was not significantly different 
between experimental and control females for week 0 (E:0.29 ± 0.06 
vs. C: 0.26 vs. 0.10) or week 12 (E:0.29 ± 0.10 vs. C:0.26 ± 0.09)(Table 
8). This hypothesis was accepted. 
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HP 1-2 Cholesterol 
H / jE :  HDI _2 was no t  significantly different at week 0 versus 
week 12 among experimental subjects. 
HDL.2 increased from week 0 to week 12 for experimental males 
(5.6 ±11.7 mg%) and experimental females (2.8± 12.4 mg%) but not 
significantly (Table 10). This hypothesis was accepted. 
H / ]C :  HDL-2  was  s ign i f i can t l y  d i f f e ren t  a t  week  0  ve rsus  week  
12 among control subjects. 
HDL.2 did not increase significantly from week 0 to week 12 (6.2 
± 12.6 mg%) for control males. HDL2 increased significantly for 
control females from week 0 to week 12 (7.7 ±_ 7.7 mg%; 
p=0.01)(Table 10). This hypothesis was rejected for males and 
accepted for females. 
H  4  -E  :C :  HDL2 was  no t  s ign i f i can t l y  d i f f e ren t  be tween  
experimental and control subjects at week 0 and week 12. 
HDL .2 was not significantly different between experimental and 
control males at week 0 (E:2 ± 2 mg% vs. C:9 ± 9 mg%) or week 12 
(E:7 ± 10 mg% vs. C: 15 ± 9 mg%)(Table 9). HDL2 was not significantly 
different between experimental and control females at week 0 (E:13 
± 9 mg% vs. C: 8 ± 2 mg%) or week 12 (E:16 ± 14 mg% vs. C:15 ± 8 
mg%). (Table 9). This hypothesis was accepted. 
HDL3 Cholesterol 
H5E:  HDL3 was no t  significantly different at week 0 versus 
week 12 among experimental subjects. 
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HDI-3 was not significantly different at week 0 versus week 12 
for experimental males (-0.3 ± 9.7 mg%) (Table 10). HDL3 decreased 
significantly from week 0 to week 12 for experimental females (-
13.9 ±.12.7; p=0.002). This hypothesis was accepted for males and 
rejected for females. 
JHjjC.: HDL3 was significantly different at week 0 versus week 
12 among control subjects. 
HDL3 did not decrease significantly from week 0 to week 12 for 
con t ro l  ma les  ( -0 .2  ±_  24 .0  mg%)(Tab le  10 ) .  HDL3  dec reased  
significantly from week 0 to week 12 for control females (-16.3 ± 
20.4; p=0.04). This hypothesis was accepted for females and 
rejected for males. 
H  5 -E  :C :  HDL3 was  no t  s ign i f i can t l y  d i f f e ren t  be tween  
experimental and control subjects at week 0 and week 12. 
HDL3 was not significantly different between experimental and 
control males for week 0 (E:39 ± 9 mg% vs. C: 42 ± 21 mg%) or week 
12 (E: 39 ±. 0 mg% vs. C:42 ±.11 mg%)(Table 9). HDL3 was not 
significantly different between experimental and control females 
for HDL3 at week 0 (E:50 ±13 mg% vs. C:58 ± 20 mg%) or week 12 (E: 
33 ±. 14 mg% vs. C:44 ±. 12 mg%)(Table 9). This hypothesis was 
accepted. 
Serum and Dietary Zinc and Cooper Zinc 
Initial dietary zinc (E:9.6 ± 5.8 mg/day vs. C:11.7 ± 2.4 mg/day), 
initial serum zinc (E:120 ±. 35 ug/dl vs. C:90 ±. 32 ug/dl) or final 
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serum zinc (E:70 ± 31 ug/dl vs. C:93 ± 3 ug/dl)(Table 11) were not 
significantly different between experimental and control males. 
Initial dietary zinc (E:8.9 ±. 4.0 mg/day vs. C:8.9 ±. 3.3 mg/day), 
initial serum zinc (E:115 ±. 36 ug/dl vs. C:100 ±. 22 ug/dl) or final 
serum zinc (E:91 ± 18 ug/dl vs. C:91 ± 27 ug/dl)(Table 11) were not 
significantly different between experimental and control females. 
Serum Zinc. Normal serum zinc was defined as 101-139 ug/dl; 
marginal serum zinc was defined as 80-100 ug/dl; and deficient 
serum zinc was defined as <80 ug/dl (Table 12). According to these 
criteria, by the end of the 12 weeks, the percentage of males 
classified as normal decreased from 50.0 percent at week 0 to 13.0 
percent at week 12; the percentage of males classified as marginal 
increased from 25.0 percent to 50.0 percent; and the percentage of 
males classified as deficient increased from 25.0 percent to 37.0 
percent (Table 12). The percentage of females classified as normal 
decreased from 52.4 percent to 14.0 percent; the percentage of 
females classified as marginal increased from 33.3 percent to 43.0 
percent; and the percentage of females classified as deficient 
increased from 14.3 percent to 43.0 percent (Table 12). 
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Table 11 
Initial and Final Mineral Profile of Study Population (Medians and 
Standard Deviations! 
Males Females 
Groups Zinc Placebo Zinc Placebo 
(n) (3) (5) (12) O) 
Initial 
Dietary 
Zinc 
(rng) 
9.6 ±5.8 11.7 ±2.4 8.9 ±43.0 8.9 ±3.3 
Initial 
Serum 
Zinc 
(ug/dl) 
120 ±35 90 ± 32 115 ±36 100 ± 22 
Final 
Serum 
Zinc 
(ug/dl) 
70 ±31 93 ± 3 91 ±18 91 ±27 
Initial 
Dietary 
Copper 2 .0 ± 2.6 2.2 ± 2.1 2.0 ± 2.3 2.0 ± 2.4 
(mg) 
Initial 
Serum 
Copper 
(ug/dl) 
110 ±26 120 ± 15 124 ±38 146 ±38 
Final 
Serum 
Copper 
(ug/dl) 
80 ±17 110 ± 13 94 ±14 98 ±43 
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Table 12 
Zinc Distribution Among Study Population at Week 0 
Males Females 
(n = 8) (n = 21) 
1 
Serum Zinc: 
Initial Final Initial Final 
4 1 11 3 
(50.0%) (13.0 %) (52.4 %) (14.0 %) 
2 4 7 9 
(25.0 %) (50.0 %) (33.3 %) (43.0 %) 
Deficient (< 80 ug/dl) 2 3 3 9 
2 (25.0 %) (37.0 %) (14.3 %) (43.0 %) 
Normal (101-139 ug/dl) 
Marginal (80-100 ug/dl) 
Dietary Zinc: 
i. RDA (>15 mg/day) 0 2 
(9.5 %) 
Marginal (<15->12 mg/day) 2 1 
(25 %) (4-8 %) 
Deficient (<12 mg/day) 6 18 
(75 %) (85 %) 
1 
Grant, A. and DeHoog, G. (1985). Nutritional Assessment Guidelines. Seattle, WA.: 
Northgate Station. 
64 
Mean serum zinc status decreased during the 12 week exercise 
program (Table 13). The decrease in zinc status was not significant 
for experimental males (-46 ± 66 ug/dl), control males (-22 ± 33 
ug/dl) or control females (-14 ±. 27 ug/dl). Zinc status decreased 
significantly for experimental females (-37 ±_ 27 ug/dl; 
p=0.007)(Table 13). 
Table 13 
Paired Comparisons T-Test of Zinc and Copper {Mean Difference Scores and 
Standard Deviations) 
Variable Males Females 
Zinc Placebo Zinc Placebo 
(n) (3) (5) (12) (9) 
Serum 
Zinc 
Difference 
(Final-Initial) -46±66 -22±33 -37±27 -14±27 
p-value 0.35 0.27 0.007 0.25 
Serum 
Copper 
Difference 
(Final-initial) -33 ±.15 -33 ±.20 -39 ±27 -19±34 
p-value 0.06 0.04 0.004 0.21 
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Dietary Zinc. Dietary zinc levels were defined as follows: 
normal > 15 mg/day 
marginal = 12-15 mg/day 
deficient < 12 mg/day 
At the beginning of the program, the zinc intake of 9.5 percent 
of the women was equal to or more than the RDA. The zinc intake for 
all the men was less than the RDA. The intake of 25 percent of the 
men and 4.8 percent of the women was marginal. The intake of 85 
percent of the women and 75 percent of the men was deficient 
(Table 12) . 
Only four study participants returned dietary records at the end 
of the program. This lack of response prohibited an evaluation of 
final dietary zinc and copper at the end of the 12 week program. 
Copper 
Initial dietary copper (E:2.0 ± 2.6 mg/day vs. C:2.2 ± 2.1 mg/day), 
initial serum copper (E:110 ± 26 ug/dl vs. 120 ± 15 ug/dl) or final 
serum copper (E:80 ±17 ug/dl vs. C:110 ± 13 ug/dl)(Table 11) was 
not significantly different between experimental and control males. 
Initial dietary copper (E:2.0 ± 2.3 mg/day vs. 2.0 ± 2.4 mg/day), 
initial serum copper (E:124 ± 38 ug/dl vs. C:146 ± 38 ug/dl) or final 
serum copper (E:94 ±14 ug/dl vs. C:98 ± 43 ug/dl)(Table 11) were 
not significantly different between experimental and control 
females. Again, as with dietary zinc, the lack of dietary records 
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prohibited analysis of final dietary copper intake for the E and C 
groups. 
Serum Copper. Normal serum copper levels were defined as 75-
150 ug/dl; marginal serum copper levels were 45-75 ug/dl; and 
deficient serum copper levels were <45 ug/dl (Table 14). Compared 
to these criteria, by the end of the 12 weeks, the percentage of 
males classified as normal decreased from 100 percent to 75 
percent; the percentage of males classified as marginal increased 
from 0 percent to 12.5 percent; and the percentage of males 
classified as deficient increased from 0 percent to 12.5 percent. 
The percentage of females classified as normal decreased from 100 
percent to 81.0 percent; the percentage of females classified as 
marginal increased from 0 percent to 5.0 percent; and the percentage 
of females classified as deficient increased from 0 percent to 14.0 
percent(Table 14). 
Dietary Copper. Dietary copper levels were defined as follows: 
normal > 2 mg/dl 
marginal = 1-2 mg/day 
deficient < 1 mg/day 
According to these criteria, 50 percent of males and 38.1 
percent of females had normal copper intake. The intake of 12.5 
percent males and 52.4 percent of females was marginal. Finally, the 
intake of 37.5 percent of males and 9.5 percent of females was 
deficient (Table 14). 
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Table 14 
Copper Distribution among Study Population at Week 0 
Males Females 
(n = 8) (n = 21) 
1 
SgrMm Copper; Initial Final Initial Final 
Normal (75-150 ug/dl) 8 6 21 17 
(100 %) (75.0 %) (100 %) (81.0%) 
Marginal (75-45 ug/dl) 
Deficient (< 45 ug/dl) 
2 
Dietary Copper: 
& RDA (> 2 mg/day) 
1 1 
(12.5 %) (05.0%) 
1 3 
(12.5 %) (14.0%) 
4 8 
(50.0 %) (38.1%) 
Marginal (<2->1 mg/day) 1 11 
(12.5%) (52.4%) 
Deficient (<1 mg/day) 3 2 
(37.5%) (9.5 %) 
1 
Grant, A. and DeHoog, G. (1985). Nutritional Assessment Guidelines. Seattle, WA.: 
Northgate Station. 
Recommended Dietary Allowances (9th edition). Normal dietary copper status 
is defined as greater than or equal to 2 mg/day copper. Marginal copper status 
is defined as less than 99-80% RDA. Deficient copper status is defined as less 
than 80% RDA. 
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Copper status decreased for experimental males (-33 ±.15 
ug/dl; p=0.06) which approached significance (Table 13). Copper 
status decreased significantly for control males (-33 ±. 20 ug/dl; 
p=0.04) and experimental females (-39 ± 27 ug/dl; p=0.004). Copper 
status did not decrease significantly for control females (-19 ±. 34 
ug/dl ). 
Zinc. Copper and Blood Lipids 
The following hypotheses were tested to identify any 
relationships between zinc, copper and blood lipids: 
JH.6: There was a direct association between serum zinc and TC 
for males and females. 
No statistically significant correlations were observed for total 
cholesterol and initial serum zinc (r=0.02) or for total cholesterol 
and final serum zinc (r=-0.55) (Table 14) for males. No significant 
correlations were observed between total cholesterol and initial 
serum zinc (r=0.09) or for total cholesterol and final serum zinc 
(r=0.41) for females. This hypothesis was rejected. 
JI7: There was an inverse association between serum zinc and 
HDL-C for males and females. 
For males, HDL-C and initial serum zinc (r=-0.25)(Table 15) 
were not significantly related, but HDL-C and final serum zinc 
(r=0.89; p=0.007) were significantly related. No significant 
associations were observed between HDL-C and initial serum zinc 
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(r=-0.13) or HDL-C and final serum zinc (r=-0.14) for females. This 
hypothesis was rejected. 
Table 15 
Spearman Correlation Coefficients of Lipid Variables {Initial and Final Values! 
and Initial and Final Zinc 
M?l? Comparison Female Comparison 
Variable Initial 
Serum 
Final 
Serum 
Initial 
Serum 
Final 
Serum 
Zinc Zinc Zinc Zinc 
(n )  (8) (8) (21) (21) 
Total Cholesterol 0.02 -0.55 0.09 0.41 
p value 0.95 0.19 0.71 0.06 
HDL Cholesterol -0.25 0.89 -0.13 -0.14 
p value 0.54 0.007 0.58 0.57 
HDL-C:TC -0.42 0.70 -0.32 -0.09 
p value 
0.32 0.07 0.14 0.70 
HDL Cholesterol 
2 
0.19 0.87 0.11 -0.06 
p value 0.64 0.01 0.60 0.81 
HDL Cholesterol 
3 
0.20 -0.07 0.47 0.23 
p value 0.64 0.87 0.03 0.36 
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Us: There was an inverse association between serum zinc and 
HDL-C:TC for males and females. 
No significant correlations were observed between the initial 
HDL-C: TC ratio and initial serum zinc (r=-0.42) or for the 
correlation between final HDL-C: TC ratio and final serum zinc 
(r=0.70)(Table 15) for males. For females, no significant 
correlations were observed between the initial HDL-C: TC ratio and 
initial serum zinc (r=-0.32), or the final HDL-C: TC ratio and final 
serum zinc (r=-0.09). This hypothesis was rejected. 
Hg: There was no inverse association between HDL2 and serum 
zinc. 
No significant correlation was observed between HDL2 
cholesterol and initial serum zinc (r=0.19), but HDL2 and final serum 
zinc were significantly correlated (r=0.87; p=0.01)(Table 15) for 
males. No significant correlations were observed for HDL2 
cholesterol and initial serum zinc (r=0.11) or HDL2 and final serum 
zinc (r=-0.06) for females. This hypothesis was accepted. 
H.10-' There was no significant association between HDL3 and 
serum zinc. 
No significant correlations were observed for HDL3 cholesterol 
and initial serum zinc (r=0.20) or HDL3 cholesterol and final serum 
zinc (r=-0.07)(Table 15) for males. No significant correlations were 
observed for HDL3 cholesterol and final serum zinc (r=0.23), but 
HDL3 cholesterol and initial serum zinc were significantly 
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correlated (r=0.47; p=0.03) for females. This hypothesis was 
accepted for males and for HDL3 and final serum zinc for females. 
The hypothesis was rejected for HDL3 and initial serum zinc for 
females. 
H.11 • There was an inverse association between obesity and 
zinc. 
There was no statistically significant correlation among 
males for initial serum zinc and BMI (r=0.07), for initial serum zinc 
and skinfold (r=0.37), for initial serum zinc and percent body fat 
(r=0.46), for initial serum zinc and total body weight (r=0.09). There 
was no statistically significant relationship between final serum 
zinc and BMI (r=-0.32), final serum zinc and skinfold (r=-0.39), final 
serum zinc and percent body fat (r=-0.28), or final serum zinc and 
total body weight (r=0.00)(Table 16). 
There were no statistically significant correlations among 
females for initial serum zinc and BMI (r=-0.10), for initial serum 
zinc and skinfold (r=0.09), for initial serum zinc and percent body 
fat (r=-0.04), for initial serum zinc and total body weight (r=-0.26), 
for final serum zinc and BMI (r=-0.01), for final serum zinc and total 
body weight (r=-0.004), for final serum zinc and skinfold (r=0.10), or 
for final serum zinc and percent body fat (r=-0.02)(Table 16). This 
hypothesis was rejected for males and females. 
H_12: There was an inverse association between the 
zinc/copper ratio and the HDL-C: total cholesterol ratio. 
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Table 16 
Spearman Correlation of Serum Zinc and Body Composition Parameters 
(Initial and Final Values) for Males and Females 
m? Comparison Female Comparison 
Variable Initial Final Initial Final 
Serum Serum Serum Serum 
Zinc Zinc Zinc Zinc 
(n) (8) (8) (21) (21) 
BMI 0.07 -0.32 -0.10 - 0.01 
p-value 
0.87 0.48 0.67 0.97 
Skinfold 0.37 -0.39 0.09 0.10 
p-value 
0.35 0.37 0.71 0.69 
% Body Fat 0.46 -0.28 -0.04 - 0.02 
p-value 
0.25 0.53 0.84 0.92 
Total Body 
Weight 0.09 0.00 -0.26 - 0.004 
p-value 0.84 1.00 0.26 0.98 
There were no significant inverse correlations between the 
zinc/copper ratio and HDL-C:total cholesterol ratio for experimental 
males (r=0.50) or for experimental females (r=-0.22)(Table 17). 
There were no significant inverse correlations between the 
zinc/copper ratio and HDL-C:total cholesterol ratio for control 
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males (r=0.81; p=0.02) or control females (r= 0.08). This hypothesis 
was rejected. 
Table 17 
Spearman Correlation Coefficients of Zn/Cu Ratio Differences and 
HPL-C:TC Ratio Differences 
Male Comparison Female Comparison 
Variable Zn/Cu Zn/Cu Zn/Cu Zn/Cu 
Ratio Ratio Ratio Ratio 
Difference Difference Difference Difference 
. . (Zinc) (Placebo) (Zinc) (Placebo) 
(3) (5) (12) (9) 
0.50 0.81 -0.22 0.08 
0.20 0.02 0.32 0.72 
H_i 3: There was an inverse association between 
activity/fitness and zinc. 
No significant inverse correlation was observed between zinc 
and fitness as measured by the mile walk administered at the 
beginning and end of the 12 week exercise program (Table 18). No 
significant correlation was observed for males between serum zinc 
and initial walk time (r=-0.14) or between serum zinc and final walk 
time (r=0.65). For female subjects, no significant correlation was 
observed between serum zinc and initial walk time (r=0.13) or 
HDL-C:TC 
Ratio 
Difference 
p-value 
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between serum zinc and final walk time (r=-0.01)(Table 18). This 
hypothesis was rejected for males and females. 
Table 18 
Spearman Correlation Coefficients for Initial and Final Walk 
Time? . 
Variable Males Females 
Initial Final Initial Final 
Walk Walk Walk Walk 
Time Time Time Time 
(8) (8) (21) (21) 
Total Cholesterol 0.59 0.10 0.33 0.34 
p-value 0.11 0.81 0.13 0.14 
HDL Cholesterol -0.55 -0.03 -0.44 0.23 
p-value 0.15 0.93 0.04 0.33 
HDL Cholesterol 
2 
0.21 -0.52 0.28 0.33 
p-value 0.61 0.22 0.20 0.16 
HDL Cholesterol 
3 
-0.73 -0.18 -0.04 0.02 
p-value 0.03 0.69 0.83 0.92 
Serum Zinc -0.14 0.65 0.13 - 0.01 
p-value 0.73 0.11 0.56 0.97 
Body Fat 0.46 -0.28 -0.04 -0.02 
p-value 0.25 0.53 0.84 0.92 
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CHAPTER V 
DISCUSSION 
High levels of zinc supplementation have been associated with 
increased total cholesterol and decreased HDL cholesterol (Klevay, 
1973). No research is available on the effects of zinc 
supplementation on HDL2-cholesterol and HDL3-cholesterol in a 
population of overweight/obese subjects. The present investigation 
was begun to establish the effects of low level zinc 
supplementation on total cholesterol, HDL cholesterol, HDL2-
cholesterol and H D L3-cholesterol. The low level of zinc 
supplementation (15 mg) was the same dose used in most vitamin 
supplements. Since the supplement dose was quite low, few 
statistically significant differences in lipid profiles following zinc 
supplementation were expected. Consequently, the exercise training 
was expected to favorably alter lipid profiles among the placebo 
group, but probably not among the experimental (zinc supplemented) 
group. 
This discussion will focus on the findings according to the 
specific hypotheses tested and the relationship of these hypotheses 
to previous findings reported in the literature. This discussion 
includes a review of the problems experienced in implementing the 
study and the limitations encountered in evaluating the results. 
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As established in the preceding results, experimental and 
control subjects, according to each gender evaluated, did not differ 
significantly in age, height, weight, body mass index, sum of 
skinfolds and percent body fat at the beginning of the 12 week 
exercise/zinc supplementation regimen (Tables 2 and 3). By the end 
of the program, there were no significant differences between 
experimental and control subjects, male and female, for final 
weight, final skinfold, final percent body fat or final BMI (Table 3 ). 
By the end of the 12 week program, subjects lost weight and body 
fat. Only control females lost a percentage of body fat that was 
statistically significant(-1.1 ± 1.5; p=0.006)(Table 5). Fitness level, 
as measured by mile walk time, improved significantly only among E 
and C females (E:-1.23 ±. 1.71 minutes; p=0.03) vs. (C:-1.10 ±1.10 
minutes; p=0.03)(Table 7). 
Serum zinc declined for all subjects but not significantly for 
three of four groups. For E females, the decrease was statistically 
significant(-37 ug/dl ± 27; p=0.007)(Table 14). Normal serum zinc 
was defined as 101-139 ug/dl; marginal serum zinc was defined as 
80-100 ug/dl; and deficient serum zinc was defined as <80 ug/dl 
(Table 12). According to these criteria, by the end of the 12 weeks, 
the percentage of males classified as normal decreased from 50.0 
percent to 13.0 percent; the percentage of males classified as 
marginal increased from 25.0 percent to 50.0 percent; and the 
percentage of males classified as deficient increased from 25.0 
percent to 37.0 percent (Table 12). The percentage of females 
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classified as normal decreased from 52.4 percent to 14.0 percent; 
the percentage of females classified as marginal increased from 
33.3 percent to 43.0 percent; and the percentage of females 
classified as deficient increased from 14.3 percent to 43.0 
percent(Table 12). 
At the beginning of the program, the zinc intake of 9.5 percent 
of the women was equal to or more than the RDA. The zinc intake for 
all the men was less than the RDA. The intake of 25 percent of the 
men and 4.8 percent of the women was marginal. The intake of 85 
percent of the women and 75 percent of the men was deficient 
(Table 12) . 
Fifty percent of males and 38.1 percent of females had normal 
copper intake. The intake of 12.5 percent males and 52.4 percent of 
females was marginal. Finally, the intake of 37.5 percent of males 
and 9.5 percent of females was deficient (Table 13). 
The decrease in copper status was not significant for 
experimental males (-33 ±. 15 ug/dl ) or control females (-19 ± 34 
ug/dl). Copper status decreased significantly for control males (-33 
±. 20 ug/dl; p=0.04), and experimental females (-39 ±. 27 ug/dl; 
p=0.004)(Table 14). 
Hypothesis Testing 
On the basis of the statistical analysis obtained for each 
hypothesis presented in the results, the following conclusions were 
developed for the specific lipid variables evaluated. In the 
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following section, each hypothesis is reviewed and compared to 
previously cited, relevant studies. 
Lipid? 
Total Cholesterol (TCI. 
JtLidE: Total cholesterol levels were not significantly different 
between week 0 and week 12 among either experimental males or 
experimental females (Table 10). 
Total cholesterol levels were not significantly different 
between week 0 and week 12 among either control males or control 
females (Table 10). 
H i  -E:C:  Cholestero l  va lues a t  weeks 0  and 12 were not  
significantly different between experimental and control males 
(Table 8). Total cholesterol at week 12 was not significantly 
different between experimental and control females. 
These results are consistent with Crouse et al. (1984), 
Freeland-Graves et al. (1980), Hooper et al. (1980) and Black et al. 
(1988) who found zinc supplementation had no significant effect on 
total cholesterol. 
A high percentage of the subjects had elevated cholesterol. This 
may have been a result of their sedentary lifestyle, their diet or 
their overweight. 
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HDL Cholesterol (HDL-C). 
tL2Ei HDL cholesterol levels increased significantly (5.6 ± 2.3 
mg%; p=0.05) between week 0 and week 12 among experimental 
males, but did not increase significantly for experimental females 
(Table 10). 
HgC:  HDL cholestero l  leve ls  were not  s ign i f icant ly  d i f ferent  
between week 0 and week 12 among either control males or control 
females (Table 8). 
Hg-E:C:  HDL-C was not  s ign i f icant ly  d i f ferent  between 
experimental and control males for weeks 0 and 12 (Table 10). HDL-
C was not significantly different between experimental and control 
females for week 12. 
These results differ from Hooper et al. (1980), Goodwin et al. 
(1985) and Black et al. (1988). Hooper et al. (1980), using a 220 mg 
supplement, found HDL-C decreased 25 percent below baseline, i.e., 
from 40.5 to 30.1 mg/dl among experimental subjects. Goodwin et 
al. (1985) found low HDL-C among those subjects on supplemental 
zinc (>15 mg/day). Black et al. (1988) found HDL-C significantly 
lower (p<0.05) at weeks 6 (53 mg%), 8 (51 mg%), and 12 (54 mg%) 
among subjects taking 75 mg zinc per day during the 12 week study 
than at week 0 (63 mg%). Among subjects taking 50 mg zinc per day, 
Black et al. (1988) found experimental subjects had lower serum 
HDL-C levels at week 12 (55 mg%) than control subjects (63 mg%). 
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HDL-C:TC Ratio. 
H31E1 HDL-C:TC levels were not significantly different between 
week 0 and week 12 for either experimental males or experimental 
females (Table 10). 
hL3^Q.: HDL-C:TC level was not significantly different between 
week 0 and week 12 for either control males or control females 
(Table 10). 
H3-E:C:  The HDL cholestero l : to ta l  cho lestero l  ra t io  was not  
significantly different between experimental and control males at 
weeks 0 and 12 (Table 8) nor between experimental and control 
females for weeks 0 and 12. None of the other researchers reported 
HDL-C:total cholesterol ratios. 
Because researchers have only recently begun to explore the 
following variables, e.g., HDL2 and HDL3 cholesterol, some of the 
variables considered in the following hypotheses have not been 
considered in any of the studies previously cited. Nevertheless, 
since zinc has elicited changes on HDL-C (Hooper et al., 1980; 
Freeland-Graves, 1980; Goodwin, et al., 1985; Black et al., 1988), an 
investigation of the effect of zinc on HDL2 and HDL3 cholesterol 
seems warranted. 
HDLg Cholesterol. 
H4E:  HDl_2 was not  s ign i f icant ly  d i f ferent  between week 0  and 
week 12 for experimental males or experimental females (Table 10). 
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H/|C: HDL2 was not significantly different for control males but 
significantly increased (7.7 ± 7.7 mg%; p=0.01) for control females 
between week 0 and week 12 (Table 10). 
H/ \  -E :C:  HDL2 was not  s ign i f icant ly  d i f ferent  between 
experimental and control males at weeks 0 or 12 (Table 9). HDL2 
was not significantly different between experimental and control 
females at weeks 0 and 12. 
HDl_2 increased s ign i f icant ly  on ly  for  cont ro l  females.  
Nevertheless, median HDL2 increased for all groups. This effect was 
anticipated since HDL2 increases in response to exercise (Goldberg & 
Elliot, 1985). Control females did not take a zinc supplement that 
might have suppressed HDL2 levels (Hooper et al, 1980; Freeland-
Graves et al., 1980; Goodwin et al., 1985; Black et al., 1988). Zinc 
supplementation may have been responsible for the lack of a 
statistically significant increase in HDL2 among experimental 
females or males. However, since the relative magnitude of change 
observed for males was similar to that observed for C females, the 
lack of a significant change was probably a reflection of the smaller 
sample size and two-fold greater variability in the C and E male 
groups. 
HDL3 Cholesterol. 
H5E:  HDL3 was not  s ign i f icant ly  d i f ferent  a t  week 0  versus 
week 12 for experimental males (Table 10). HDL3 decreased 
significantly (-13.9 ± 12.7 mg%; p=0.002) between week 0 and week 
12 for experimental females. 
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H5C: HDL3 was not significantly different at week 0 versus 
week 12 for control males (Table 9). HDL3 decreased significantly 
(-16.3 ± 20.4 mg%; p=0.04) between week 0 and week 12 for control 
females. 
H5-E:C:  HDL3 was not  s ign i f icant ly  d i f ferent  between 
experimental and control males for weeks 0 and 12 (Table 9). HDL3 
was not significantly different between experimental and control 
females for HDL3 weeks 0 and 12. 
Median HDL3 remained relatively constant for males but 
decreased significantly for both E and C females. Thus, the decrease 
occurred in spite of zinc supplementation. Exercise, diet, weight 
loss or the combined effect of exercise, diet and weight loss may 
have contributed to the change. Suntsov, Zhukovskii, Poleskii and 
Kundraykova (1987) found that hyperinsulinemia decreases HDL3. 
They stated that derangements in the metabolism of HDL3 would 
likely be associated with a high risk of coronary heart disease 
development especially among patients with diabetes mellitus. 
Therapeutic measures aimed at reducing insulin secretion were 
recommended for the normalization of lipid metabolism including 
HDL3. Exercise and weight loss positively affect diabetes mellitus 
(Zeman, 1983). Fitness improved and body weight decreased for 
subjects in this dissertation research. Therefore, it would seem 
that  d ie t  probably  had more to  do wi th  the reduct ion o f  HDL3 than 
fitness or body weight. In the absence of final dietary assessment, 
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however, the extent to which diet affected HDL3 can only be 
speculated . 
H_6: Neither total cholesterol and initial serum zinc nor total 
cholesterol and final serum zinc were significantly correlated 
among either male or female subjects (Table 10). 
No study specifically considered this correlation. However, 
Freeland-Graves et al. (1980) observed a weak correlation of whole 
blood zinc with plasma cholesterol (r=-0.17; p<0.03) in their sample 
of 32 subjects. 
While Klevay did not conduct human studies in which the 
relationship between total cholesterol and serum zinc was evaluated 
by correlation calculation, he has stated that high levels of zinc can 
contribute to hypercholesterolemia. Apparently, in this dissertation 
research, the level of zinc supplementation was inadequate to affect 
either serum zinc or, total cholesterol. 
JH_7: For males, HDL-C and initial serum zinc were not 
significantly correlated, but HDL-C and final serum zinc were 
significantly correlated (r=0.89; p=0.007). Neither HDL-C and 
initial serum zinc nor HDL-C and final serum zinc were 
significantly correlated for females (Table 15). 
The significant positive correlation observed among the males 
is in contrast to a negative correlation for plasma zinc versus HDL-C 
(r=-0.22; p<0.005) reported by Freeland-Graves et al. (1980). In this 
study, however, the significant positive correlation occurred among 
males whereas Freeland-Graves et al. (1980) evaluated females. In 
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this dissertation research, the small number of subjects compared 
to the 32 females studied by Freeland-Graves et al. (1980) may 
have been a confounding variable. The -0.22 correlation reported by 
Freeland-Graves et al. (1980) is a very weak correlation. 
The following hypotheses have not been considered in any of the 
studies previously cited: 
Hg: Neither the correlation of HDL-C:TC ratio and initial serum 
zinc nor the correlation of HDL-C:TC ratio and final serum zinc 
were significant for males or females (Table 15). 
jig: HDL-2 cholesterol and initial serum zinc were not 
significantly correlated for males or females (Table 15). HDL2 
cholesterol and final serum zinc were significantly correlated 
(r=0.87; p=0.01) for males, but HDL2 cholesterol and final serum zinc 
were not significantly correlated for females (Table 15). 
H_10: HDL3 cholesterol and initial serum zinc and HDL3 
cholesterol and final serum zinc were not significantly correlated 
for males (Table 15). HDL3 cholesterol and final serum zinc were 
not significantly correlated for females, but HDL3 cholesterol and 
initial serum zinc were significantly correlated (r=0.47; p=0.03) for 
females. 
H_11: Neither initial nor final serum zinc were correlated with 
BMI, skinfold, percent body fat or total body weight for either males 
or females (Table 16). None of the other studies considered 
correlations of these variables. 
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Only Crouse et al. (1984) measured body mass index and body 
weight. These measures were used to test for differences among 
the groups participating in the study. The investigators found that 
one of the groups in the study, the endurance trained subjects, had a 
lower body mass index (p<0.01) and weighed less (p<0.01) than 
another group in the study, the sedentary group. The investigators 
did not attempt to correlate BMI or body weight with serum zinc. 
As stated previously (Spencer et al., 1982; Miyamura et al., 
1987; Kennedy et al., 1986; Chandra et al., 1980; Pras et al., 1983), 
body fat affects zinc status. Specifically, from studies such as 
Spencer et al. 1982), there is the anticipation of increased serum 
zinc with weight loss. However, as in this dissertation research, 
the exercise necessary for significant weight loss can also be 
accompanied by zinc loss through sweat, perhaps enough to 
sufficiently lower serum zinc (Miyamura et al., 1987). 
As stated previously, subjects were assessed by both body mass 
index and skinfold measures. BMI may not adequately reflect 
variations in body fat. As critics have charged, stature, i.e., height 
is one component of BMI, and BMI may be stature dependent over part 
of the age range (Gam et al., 1986). Measures of skinfolds at various 
appropriate body sites should reflect the body's storage fat (Katch 
and McArdle, 1983). Skinfold measurements can be used to assess 
an individual's change in percent body fat in weight reduction 
programs and before and after physical conditioning. Thus, of the 
measures used, skinfold measures and the percent body fat figures 
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derived from skinfold measures probably reflect body fat stores 
more accurately than BMI. 
Hi 2'. The zinc/copper ratio and the HDL-C:total cholesterol ratio 
were not significantly inversely correlated for experimental males, 
experimental females or control females (Table 17). Control males, 
however, had a statistically significant positive correlation (r=0.81; 
p=0.02). 
H_13: Neither serum zinc and initial walk time nor serum zinc 
and final walk time were significantly inversely correlated for 
males or females (Table 18). 
Zinc supplementation had no consistent statistically significant 
effect on lipid profiles in the present study. This lack of statistical 
significance is consistent with the findings reported by Freeland-
Graves et al. (1982). Administering a range of zinc supplementation, 
the investigators in that study found relatively high pharmacologic 
doses (100 mg) lowered HDL-C in four weeks, but no changes were 
noted with lower levels of zinc (< 50 mg/day). 
In the Black et al. (1988) study, HDL cholesterol levels in 
subjects assigned to the 75 mg zinc group were significantly lower 
than those for the placebo group at weeks 6 (E:53 mg% vs. C:61 mg%) 
and 12 (E:54 mg% vs. C:63 mg%). HDL cholesterol levels in subjects 
assigned to the 75 mg zinc group were lower at weeks 6 (53 mg%), 8 
(51 mg%), and 12 (54 mg%) than at baseline (63 mg%). Subjects in 
the 50 mg group had lower serum HDL-C levels at week 12 (55 mg%) 
than did the placebo group (63 mg%). 
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Crouse et al. (1984) concluded that "low dose zinc 
supplementation was not associated with significant alterations in 
lipid lipoprotein levels in either trained or sedentary persons." They 
did not evaluate HDL2 or HDL3 cholesterol. The lack of statistically 
significant results of this study seem to support the conclusions of 
Crouse et al. (1984), viz., that low dose (15 mg.) zinc 
supplementation does not significantly affect HDL-C. 
After administering 50 mg. zinc to E and C sedentary and 
endurance trained subjects, Crouse et al. (1984) found no statistical 
significance between experimental and control groups. None of the 
interactions between the zinc dose and the remaining independent 
factors were significant. Their findings suggested that the power of 
the statistical test may have been limited by the large variability 
associated with plasma zinc concentration or by sample size. A 
longer period of zinc administration, they said, or a trial with 
larger numbers of participants might have produced significant 
results. 
As for increasing study length, of the studies cited, only the 
study by Goodwin et al. (1985) was conducted for a longer period, 
i.e., five years. The Black et al. (1988) study was conducted for 12 
weeks, the same time span as the present investigation. 
HDL cholesterol, HDL2 cholesterol, HDL3 cholesterol values and 
HDL-C:TC ratio showed positive, statistically significant 
correlations with final serum zinc among the females (Table 15). No 
previous study has investigated the effects of either zinc 
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supplementation or exercise on HDL2 or HDL3. Thus, even in the 
absence of statistical significance, this study, by its design, has 
provided some information on the effect of zinc supplementation on 
HDI_2 and HDL3 among an exercising population. 
In a previous RESHAPE study (Bazzarre, Evans, Kinard & Truslow, 
1985), 24 percent of participants dropped out of the program by the 
end of 12 weeks. Twelve percent dropped out before completing the 
first two weeks of the program, and the remaining 12 percent 
dropped out prior to the eighth week of the study. Males were 40.2 ± 
9.8 years and females 36.8 ± 10.7 years. Body weight decreased 
significantly from 200 + 18 lbs. to 191 ± 19 lbs. (p<. 0.010) for 
males and from 158 ±.27 lbs. to 153 ±_ 25 lbs. (p<. 0.001) for 
females. Percent body fat decreased from 29 ± 5 percent to 25 ± 4 
percent (p<. 0.001) for males and from 38 ± 5 percent to 35 ± 5 
percent (p< 0.01) for females. Collectively, total cholesterol for the 
sample of 93 subjects decreased from 197 ±38 mg% to 186 ± 37 
mg% (p< 0.01); HDL-C increased from 52 ± 14 mg% to 53 ± 14 mg%; 
HDL-C:TC ratio increased from 0.27 ± 0.08 to 0.29 ± 0.08 (p< 0.01). 
Overall, participants in this dissertation research, compared to 
the previous report by Bazzarre et al. (1985), were slightly older 
and heavier, had similar body fat and HDL-C:TC ratio, had higher 
total cholesterol and varied as to HDL-C levels. Their changes over 
time were not as pronounced as changes among previous 
participants. Their dropout rate (34 percent) was greater than that 
for the previous participants (24 percent). As stated previously, 
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subjects in this dissertation research were older, fatter, more 
overweight and had higher cholesterol levels than subjects in the 
study by Bazzarre et al. (1985). In their previous research, Bazzarre 
et al. (1985) noted that individuals who had poor attendance were 
more overweight and more overfat than the other RESHAPE 
participants. One possible explanation for the higher dropout rate in 
this dissertation research, then, was that, because of their greater 
weight and fat, these participants were more prone to dropping from 
the program. 
The median total cholesterol of subjects in this study was 
either borderline-high or high according to levels set by the Adult 
Treatment Panel of the National Cholesterol Education Program (U.S. 
Dept. of Health and Human Services, 1987). These blood cholesterol 
levels were as follows: (1) desirable (less than 200 mg%), (2) 
borderline-high (200 to 239 mg%), (3) high (240 mg% and above). 
According to these criteria, initial median cholesterol levels were 
quite high for E males (253 ± 56 mg%), C males (220 ± 41 mg%) and 
C females (225 ±. 27 mg%). E females had borderline-high 
cholesterol levels (200 ± 40 mg%). By the end of the program, only C 
males had reduced their cholesterol to desirable levels (197 ±. 53 
mg%). In the previous RESHAPE study (Bazzarre et al., 1985), both 
initial and final cholesterol levels, collectively, were within 
desirable range according to the previously mentioned standards. 
According to the Adult Treatment Panel of the National 
Cholesterol Education Program (U.S. Department of Health and 
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Human Services, 1987), epidemiological studies have shown that 
people with high blood cholesterol have a greater chance of 
developing coronary heart disease than do people with lower levels 
of cholesterol, and the chances of developing coronary heart disease 
increase in proportion to the amount the cholesterol is elevated, 
especially for values over 200 mg%. In the United States, people 
with a blood cholesterol of 240 mg% or higher have more than two 
times the risk of developing heart disease as do those with a level 
of under 200 mg%. About 25 percent of adults in the United States 
have blood cholesterol levels over 240 mg% and more than half of 
U.S. adults have levels over 200 mg%. 
Overall, subjects lost weight and body fat (Table 5), and serum 
zinc and copper decreased. The weight loss could have been a 
response to the diet-exercise program: all subjects decreased walk 
times (Table 7). Walk times improved significantly for all females, 
but not for males. The improved performance suggested that the 
subjects achieved a training effect. Thus, both weight loss and 
exercise could have contributed to zinc loss. 
As previously stated, Klevay (1975) has acknowledged that the 
concentration of zinc (0.93 mg/liter) in sweat is 16 times that of 
copper (0.058 mg/liter). He has also noted that increased physical 
activity increases sweating, causes a greater loss of zinc than 
copper, and results in a lower ratio of zinc to copper. 
Klevay (1975) reported that the ratio of zinc to copper of human 
muscle and bone are 56 and 120, respectively. Thus, under the 
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stimulus of exercise, far more zinc than copper must be 
incorporated into muscle and bone from amounts absorbed from the 
intestinal tract. Relatively less zinc than copper is then likely to be 
available to the other organs such as the liver. The improved fitness 
and decreases in weight/fat loss would, therefore, be consistent 
with decreased serum copper and zinc provided the absence of 
satisfactory zinc-copper supplementation. 
Klevay (1975) noted that diets high in fat and sucrose and low in 
vegetable fiber, which have been associated with a high risk of 
coronary heart disease, contained a high zinc to copper ratio. Diets 
low in fat and sucrose and high in fiber, in addition to having a low 
zinc to copper ratio, contain substances such as fiber that reduce 
the degree to which zinc is absorbed from the intestinal tract. The 
subjects' increased intake of dietary fiber could also explain the 
decrease in zinc and copper status. 
According to Klevay (1975), the concentration of copper in the 
serum of men increases in a linear manner between the third and 
seventh decades of life. These data are consonant with a selective 
mortality due to coronary heart disease of the individuals at each 
age with a higher ratio of zinc to copper which restricts the 
measurements of copper to those who survive. In this study, male 
subjects were obese with elevated cholesterol levels. These 
subjects, then, were at risk for heart disease. 
According to Fischer et al. (1980), zinc competes with copper 
for binding to metallothionein and consequently at higher dietary 
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levels, less copper is absorbed. Fischer et al. (1980), in studies 
with rats, have determined that copper and zinc, at levels likely to 
be present in the normal mixed North American diet, can affect 
serum mineral concentration but have no effect on serum cholesterol 
levels. Helwig et al. (1979) investigated the effect of adding 
different amounts of copper and zinc to the diet of laying hens. They 
found no effect on either serum or egg cholesterol levels. Caster 
and Doster (1979) fed rats diets in which the zinc/copper ratio 
ranged from 2 to 220. No significant significant effect on mean 
plasma cholesterol was observed. Thus, some animal studies 
suggest zinc/copper ratios may not affect lipid profile. This lack of 
effect is a contradiction of the research reported by Klevay (1979). 
Zinc status could have declined as a function of the combined 
effect of exercise and diet. As stated previously, subjects in the 
Miyamura et al. (1987) study had depressed zinc levels following 
exercise. Subjects in the Dressendorfer et al. (1980) study had 
depressed zinc levels following exercise. In that study, serum zinc 
decreased with greater aerobic training. Dressendorfer et al. (1980) 
stated that the redistribution of zinc stores in the body could 
explain hypozincemia during exercise. Animal studies (Oh et al., 
1978) indicate exercise induces production of the zinc-binding 
protein metallothionein. Thus, exercise training could stimulate 
production of zinc dependent enzymes in the liver and. other tissues 
and lower circulating zinc levels. As elsewhere stated, diet could 
affect the zinc status by having included foods with zinc binding 
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agents. Perhaps subsequent research should include analysis of 
covariance of these variables to determine if their combined effect 
could account for the serum zinc reduction. 
Subsequent research might also include animal models. Animal 
research would provide an opportunity to rigorously control diet, 
graded levels of zinc and copper, specific exercise regimens of 
varying duration, the use of normal weight and genetically obese 
rodents, and various weight reduction programs. The animal model 
would also permit researchers to evaluate functional changes in 
specific tissues. 
L imi ta t ions 
This study had two major limitations: the use of free living 
subjects and the failure of most subjects to return final dietary 
records. Because subjects were free living, direct capsule 
monitoring was not possible. To have monitored supplement intake 
only when the subjects attended the daily workout sessions would 
have limited supplementation to three days a week or less, 
depending on subject attendance. The study investigator regularly 
attended the three day a week subject exercise sessions and weekly 
workshop meetings. Subjects were urged, at these sessions and 
workshops, to take their supplement and record supplement 
compliance on charts provided them. Chart data indicated they 
consistently complied. In addition, approximately 90 percent of 
subjects returned capsule containers at the end of the study. All of 
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the returned containers contained an extra two capsules. The extra 
two capsules that had been added as a check of subject compliance 
was a good monitoring system. The ideal approach would be to 
require subjects to take the supplement in the presence of the staff 
members. 
Also, as stated previously, only four study participants returned 
dietary records at the end of the program. This lack of response 
prohibited evaluating final dietary fiber, zinc and copper. These 
dietary records could have indicated whether dietary habits might 
explain the decrease in serum zinc. For example, subjects in 
RESHAPE workshops were encouraged to increase fiber and decrease 
dietary fat intake. Both measures could reduce zinc status. 
Black et al. (1988) required biweekly diet records but 
acknowledged the difficulty of monitoring dietary habits among 
subjects such as those in the present study. They stated that, among 
free living subjects, factors including diet patterns not recorded for 
each three day period could contribute to variations in expected 
results. Thus, even if subjects had completed a number of diet 
records, the possibility exists that diet could affect subjects' zinc 
status and still go undetected. Thus, a rigorous controlled feeding 
study would have been the only means of monitoring dietary intake 
compliance. 
Subsequent research might include some form of monetary 
incentive. This monetary incentive might effectively insure 
subjects' adherence and compliance to study criteria and completion. 
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A monetary incentive would be predicated on both the return of final 
dietary records (if that was a part of the program), satisfactory 
compliance with supplement/placebo ingestion and completion of all 
tes ts .  
In summary, 15 mg/day zinc supplementation had no apparent 
effect on lipid profile. Nevertheless, this supplementation was not 
enough to prevent a decrease in zinc status. Thus, individuals 
considering a weight reduction program of diet and exercise should 
be aware of the potential of decreased zinc status. Previous 
research (Freeland-Graves et al., 1980; Black et al., 1988; Goodwin 
et al., 1985) has indicated the effect of lower levels of zinc 
supplementation on lipid profile, but only Goodwin et al. (1985) has 
included an exercise component at these lower levels. None of the 
previous investigators evaluated the effect of weight loss, exercise 
and low level zinc supplementation on lipid profiles. More research 
is needed to define the effect of exercise and weight loss on zinc 
status. 
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
A sample of 47 (12 male and 35 female) participants in a 12 
week exercise program (RESHAPE) were divided into experimental 
(E) and control (C) subjects. E subjects received zinc 
supplementation (15 mg) to assess the effects of supplementation 
on total cholesterol (TC), high density lipoprotein cholesterol (HDL-
C), HDL-C:TC ratio, HDI_2 cholesterol, HDL3 cholesterol, serum zinc 
and copper at week 0 and 12. Additional objectives included 
measuring the effects of obesity and exercise on TC, HDL-C, HDL-
C:TC ratio, HDL2 and HDI_3( and serum zinc and copper at week 0 and 
12. Hypotheses generated from these objectives were tested. 
Results indicated the following: 
Percent body fat significantly decreased among control females. 
Walk time significantly decreased for control and experimental 
females. 
HDL-C significantly increased for experimental males (5.6 ± 2.3; 
p=0.05), while HDL2 significantly increased for control females (7.7 
± 7.7; p=0.01). HDL3 decreased significantly among control(-13.9 ± 
12.7; p=0.002) and experimental(-16.3 ± 20.4; p=0.04) females. 
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For control females, HDL2 (7.7 mg% ± 7.7; p=0.01) significantly 
increased, and HDL3 (-16.3 mg% ±_ 20.4; p=0.04) significantly 
decreased. The latter change was not expected. 
Serum zinc significantly decreased for experimental females (-
37 ± 27 ug/dl; p=0.007). Serum copper significantly decreased for 
both control (-33 ±_ 20 ug/dl; p=0.04) males and experimental 
females (-39 ± 27 ug/dl; 0.004). 
Final serum zinc was positively correlated with final HDL-C 
(r=0.89; p=0.007) and final HDL2 cholesterol (r=0.87; p=0.01) for 
males. Initial serum zinc was positively correlated with initial 
HDL3 cholesterol for females (r=0.47; p=0.03). The zinc/copper ratio 
difference was positively correlated with HDL-C:TC ratio difference 
for control males (r=0.81; p=0.02). Initial walk time and initial 
HDL-C were negatively correlated for females(r=-0.44; p=0.04). 
Initial HDL3 cholesterol and initial walk time were negatively 
correlated for males (r=-0.73; p=0.03). 
A number of hypotheses were confirmed when, as predicted, no 
change occurred over time. No significant change occurred over time 
for experimental subjects for TC, HDL-C:TC, and HDL2. No 
significant change occurred over time for HDL-C among experimental 
females or HDL3 among experimental males. No significant 
correlations occurred between lipid variables and initial and final 
serum zinc except for the following: final serum zinc correlated 
significantly with final HDL-C (r=0.89; p=0.007) and HDL2 
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cholesterol (r=0.87; p=0.01) for males. For females, initial serum 
zinc correlated with initial HDL3 cholesterol (r=0.47; p=0.03). 
No statistically significant correlation was observed between 
HDL2 cholesterol and serum zinc for females or between HDL3 
cholesterol and initial or final serum zinc for males. Finally, no 
correlation occurred between measures of obesity and zinc. 
Original assumptions had included both a significant 
improvement in walk times and a significant weight loss among 
subjects. The data supported these two assumptions: both E and C 
females signficantly reduced their walk times (E:-1.23 ± 1.71 
minutes; p=0.03) vs. (C:-1.10 ±1.10 minutes; p=0.03), and control 
females significantly reduced percent body fat (-1.1 ± 1.5 percent; 
p=0.006). 
Serum zinc status had originally been assumed to remain 
constant or possibly improve in the supplemented group. 
Nevertheless, the possibility existed that the combined effects of a 
weight reduction program and changes in diet, e.g., increased fiber, 
might have contributed to a decrease in zinc status. This reduction 
in serum zinc did, in fact, occur. 
This study was limited by a small sample size; the lack of 
compliance with protocol, e.g., return of final dietary records and 
the use of free living subjects. These limitations have been 
acknowledged elsewhere and remedies have been suggested. 
Subsequent research dealing with zinc supplementation and lipid 
profile should consider these factors and attempt to counteract 
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them. More active recruitment might also be used to increase the 
number of subjects. 
The implications of the present research are that zinc 
supplementation (15 mg/day) should have no deleterious effect on 
cholesterol levels. However, exercise and diet may affect zinc 
status (Miyamura et al., 1987; Dressendorfer et al., 1980; Oh et al., 
1978) The extent to which either exercise or diet alone or together 
could affect zinc status is indeterminate from this research. 
Nevertheless, persons wishing to initiate a weight loss program 
involving exercise and diet should consider the effect exercise and 
diet may have on serum zinc, take precautions to monitor serum zinc 
status, and, if advised by a physician, take the measures necessary 
to raise serum zinc to appropriate levels. 
None of the previous research has considered either the effect 
of weight loss, exercise and zinc supplementation on lipid profile or 
the effect of exercise and weight loss on zinc status. Moreover, no 
research has specifically focused on the effect of these variables, 
i.e., weight loss, exercise and zinc supplementation on obesity. 
Further research, therefore, is needed in these areas. 
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Table A-1 
Wllcoxon Two Sample Test bv Zinc Supplementation: Aae. Height. Weight 
Variable Medians for Wllcoxon Approximate 
Zinc Placebo S Value Z Score . P value 
Age 
(n) 
Initial 
Height 
(n) 
Initial 
Body 
Weight 
(n )  
Final 
Body 
Weight 
(n) 
MAIE9 
43 41 26.5 
(5) (7) 
69 
(5) 
212 
(5) 
208 
(3) 
69 
(7) 
233 
(7) 
230 
(5) 
32.0 
23.0 
23.0 
0.38 
0.00 
-0.09 
-0.09 
0.70 
1.00 
0.92 
0.92 
Age 
(n) 
Initial 
Height 
(n) 
Initial 
Body 
Weight 
(n)  
Final 
Body 
Weight 
(n) 
FEMALES 
40 39 279.5 
(17) (18) 
66 65 
(17) (18) 
166 161 
(17) (18) 
156 151 
(12) (9) 
355.0 
301.00 
23.0 
-0.60 
1.60 
0.10 
-0.09 
0.50 
0.10 
0.91 
0.92 
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Table A-2 
Descriptive Statistics of Study Population at Week 0 {Medians and Standard 
Deviations) 
Males 
Groups 
(n) 
Zinc Placebo 
Females 
Zinc Placebo 
Initial 
Weight 
(Lbs.) 
(n) 
Final 
Weight 
(Lbs.) 
(n) 
Initial 
BMI 
(n) 
Final 
BMI 
(n) 
Initial 
Skinfold 
(mm) 
(n) 
Final 
Skinfold 
(mm) 
(n )  
Initial 
Percent 
Body Fat 
(n) 
Final 
Percent 
Body Fat 
(n) 
212 ±79 
(5) 
2 0 8  ± 2 8  
<3> 
31 ±8 
(5) 
27 ±3 
(3) 
81 ±40 
(5) 
75 ±23 
(3) 
28 ± 8 
(5) 
29 ±8 
(3) 
233 ±47 
(7) 
230 ±56 
(5) 
32 ±6 
(7) 
29 ±7 
(5) 
89 ±19 
(7) 
77 ±29 
(5) 
32 ±4 
(7) 
32 ±2 
(5) 
166 ±27 
(17) 
156 ±19 
(12) 
26 ±5 
(17) 
24 ±4 
(12) 
105 ±31 
(17) 
91 ±27 
(12) 
39 ±5 
(17) 
38 ±5 
(12) 
161 ±33 
(18) 
151 ±36 
(9) 
27 ±6 
(18) 
26 ±8 
(9) 
99 ±35 
(18) 
85 ±36 
(9) 
37 ±5 
(18) 
37 ±5 
(9) 
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Table A-3 
Wllcoxon Two Sample Test bv Zinc Supplementation of Males: Percent 
Body Fat. Skinfold. BMI 
Variable Medians for Wllcoxon Approximate 
Zinc Placebo S Value Z Score P value 
Initial 
Skinfold 
(n) 
Final 
Skinfold 
(n) 
Initial 
Percent 
Body Fat 
(n) 
Final 
Percent 
Body Fat 
(n) 
81 
(5) 
75 
(4) 
31 
(5) 
31 
(4) 
89 
(7) 
77 
(5) 
32 
(7) 
32 
(5) 
Initial 
BMI 
(n) 
Final 
BMI 
(n) 
31 
(4) 
27 
(3) 
32 
(7) 
29 
(5) 
29.0 -0.49 0.62 
18.5 -0.25 0.81 
34.0 0.16 0.87 
17.0 -0.61 0.54 
21.0 -0.47 0.63 
10.0 -0.89 0.37 
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Table A-4 
Wllcoxon Two Sample Test bv Zinc Supplementation of Females: Percent 
Body Fat. Skinfold. BMI 
Variable Medians for 
Zinc Placebo 
Wllcoxon Approximate 
S Value Z Score P value 
Initial 
Skinfold 
(n) 
Final 
Skinfold 
(n) 
Initial 
Percent 
Body Fat 
( n )  
Final 
Percent 
Body Fat 
(n )  
Initial 
BMI 
(n) 
Final 
BMI 
(n) 
105 
(17) 
91 
(12) 
39 
(17) 
38 
(12) 
26 
(17) 
24 
(12) 
99 
(18) 
85 
(9) 
37 
(18) 
37 
(9) 
27 
(18) 
26 
(9) 
317.0 
317.0 
310.5 
264.5 
294.0 
80.0 
0.36 
0.36 
0.13 
-0.25 
-0.10 
-0.44 
0.72 
0.72 
0.89 
0.80 
0.92 
0.65 
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Table A-5 
Initial and Final Lipid Profile of Study Population (Medians and Standard 
Deviations) 
Groups 
(n) 
Zinc 
Males 
Placebo Zinc 
Females 
Placebo 
Initial 
Total 
Cholesterol 
(mg%) 
n 
228 ±46 
(5) 
220 ±38 
(7) 
192 ± 4 2 
(17) 
217 ±.42 
(18) 
Final 
Total 
Cholesterol 
(mg%) 258 ± 1 3 197 ±53 200 ± 50 226 ±34 
n (3) (5) (12) (9) 
Initial 
HDL 
Cholesterol 
(mg%) 33 ± 8 42 ±7 51 ± 14 52 ±17 
n (5) (7) (17) (18) 
Final 
HDL 
Cholesterol 
(mg%) 40 ± 10 57 ±7 49 ± 17 55 ±17 
n 
(3) (5) (12) (9) 
Initial 
HDL-C:TC .15 ± .06 . 21 ± .05 . 29±.08 30 ±.10 
n (5) (7) (17) (18) 
Final 
HDL-C:TC .15 ± .5 .25 ± .16 .26 ± .10 .25 ±.10 
n (3) (5) (12) (9) 
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Table A-6 
Initial and Final Lipid Data of Study Population (Medians and Standard 
Deviations) 
Groups 
(n) 
Males 
Zinc Placebo 
Females 
Zinc Placebo 
Initial 
HDL 2 
Cholesterol 
(mg%) 
n 
Final 
HDL 2 
Cholesterol 
(mg%) 
n 
Initial 
HDL 
3 
Cholesterol 
(mg%) 
n 
4±2 
(5) 
7 ±10 
(3) 
37_± 9 
(5) 
5 ±9 
(7) 
15 ±9 
(5) 
35 ± 1 9 
(7) 
10 ±9 
(17) 
16 ±14 
(12) 
46 ±12 
(17) 
8 ±4 
(18) 
15 ± 8 
(9) 
54 ± 20 
(18) 
Final 
HDL 
Cholesterol 
(mg%) 
n 
39_± 0 
(3) 
42 ± 1 1 
(5) 
33 ±14 
(12) 
44± 1 2 
(9) 
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Table A-7 
Wllcoxon Two Sample Test of Lipid Variables bv Zinc Supplementation of 
Males 
Variable Medians for 
Zinc Placebo 
Wllcoxon Approximate 
S Value Z Score P value 
Initial 
Total 
Cholesterol 
(n) 
228 
(5) 
228 
(7) 
38.5 0.89 0.37 
Final 
Total 
Cholesterol 
(n) 
258 
(3) 
221 
(5) 
20.0 1.80 0.15 
Initial 
HDL 
Cholesterol 
(n )  
33 
(5) 
42 
(7) 
20.5 -1.89 0.06 
Final 
HDL 
Cholesterol 
(n) 
Initial 
HDL-C:TC 
Ratio 
(n) 
40 
(3) 
15 
(5) 
57 
(5) 
22 
(7) 
9.50 
21.0 
- 1.05 
-1.78 
0.13 
0.07 
Final 
HDL-C:TC 
Ratio 
(n) 
15 
(3) 
25 
(5) 
8.00 -1.50 0.22 
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Table A-8 
Wllcoxon 2-Sample Test bv Zinc Supplementation of Males 
Variable Medians for Wllcoxon Approximate 
Zinc Placebo S Value Z Score P value 
Initial 
HDL 2 
(n)  
Final 
HDL 
2 
( n )  
Initial 
HDL 
3 
(n) 
Final 
HDL 
3 
(n)  
4 
(5) 
1 
(3) 
37 
(5) 
39 
(3) 
5 
(7) 
12 
(5) 
35 
(7) 
42 
(5) 
21.0 
10.0 
30.5 
12.0 
-1.56 
26.00 
0.00 
-0.30 
0.12 
0.30 
1.00 
0.70 
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Table A-9 
Wllcoxon Two Sample Test of Lipid Variables bv Zinc Supplementation of 
Females 
Variable Medians for 
Zinc Placebo 
Wllcoxon Approximate 
S Value Z Score P value 
Initial 
Total 
Cholesterol 
(n) 
Final 
Total 
Cholesterol 
(n) 
Initial 
HDL 
Cholesterol 
(n) 
Final 
HDL 
Cholesterol 
(n) 
192 
(17) 
200 
(12) 
51 
(17) 
49 
(12) 
217 
(18) 
226 
(9) 
52 
(18) 
55 
(9) 
266.00 
113.50 
293.50 
111.00 
-1.30 
0.99 
-0.39 
0.82 
0.19 
0.20 
0.69 
0.57 
Initial 
HDL-C:TC 
Ratio 
(n) 
26 
(17) 
30 
(18) 
314.00 0.25 0.80 
Final 
HDL-C:TC 
Ratio 
(n )  
26 
(12) 
25 
(9) 
94.00 0.32 0.73 
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Table A-10 
Wllcoxon 2-Sample Test of Median Lipid Scores for Females 
Variable Medians for Wllcoxon Approximate 
Zinc Placebo S Value Z Score P value 
Initial 
HDL 2 
(n) 
Final 
HDL 
2 
(n) 
Initial 
HDL 
3 
(") 
Final 
HDL 
3 
(n )  
10 
(16) 
13 
(12) 
46 
(17) 
33 
(12) 
8 
(17) 
12 
(9) 
54 
(18) 
44 
(9) 
262.0 
102.00 
280.5 
118.5 
0.33 
0.17 
-0.83 
1.35 
0.58 
0.85 
0.40 
0.37 
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Table A-11 
flpid status according to level of obesity for males and females at week 0 
Medians and Standard Deviations! 
1 
BMI 
2 
% Body Fat 
<25 25-29.9 i3 0 normal overweight obese 
Total 
Cholesterol 
(mg%) 
270 ±71 
(2) 
249 ±27 
(2) 
MALES: 
213 ±35 220 
(8) (1) 
229 ±1 
(2) 
230 ±50 
(9) 
HDL-C 
(mg%) 
42 ±13 43 ±14 41 ±7 52 46 ±9 40 ±7 
(2) (2) (8) (1) (2) (9) 
HDL-C:TC 1 6 ±9 17 ±7 19 ±4 23 20 ±4 19 ±5 
ratio (2) (2) (8) (1) (2) (9) 
HDL 
2 
2 ±2 4 ±1 6 ±8 50 42 ±7 6 ±8 
(mg%) (2) (2) (8) (1) (2) (9) 
HDL 40 ±13 46 ±1 38 ±1 7 1 4 ±1 38 ±17 
3 
(mg%) (2) (2) (8) (1) (2) (9) 
FEMALES: 
Total 
Cholesterol 
(mg%) 
214 ±31 
(12) 
198 ±37 
(12) 
197 ±56 
(11) 
213 ±63 
(2) 
202 ±42 
(33) 
HDL-C 
(mg%) 
64 ±16 
(12) 
53 ±13 
(12) 
51 ±15 
(11) 
77 ±28 
(2) 
55 ±15 
(33) 
HDL-C:TC 30 ±8 27 ±9 29 ±13 35 ±2 28 ±10 
ratio (12) (12) (11) (2) (33) 
HDL 
2 
10 ±8 6 ±5 1 1 ±6 9 ±1 9 ±7 
(mg%) (12) (12) (11) (2) ' (33) 
HDL 
3 
57 ±17 55 ±1 7 47 ±15 74 ±19 52 ±16 
(mg%) (12) (12) (11) (2) (33) 
weight ^a)Overweiaht is 25-29.9 kg-m weight for height. 
height (m) - 2 
Obesity is greater than or equal to 30 kg-m weight for height. 
2. Percent body fat estimated from sum of four skinfolds (Durnin 
and Womersley, 1973). Overweight is 20-28 percent and 22-30 
percent for males and females, respectively. Obesity is greater 
than 28 percent and greater than 30 percent for males and females, 
respectively. 
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Table A-12 
Serum zinc status according to level of obesltv for males and females 
at week 0 (Means and Standard Deviations) 
<25 
1 
BMI 
25-29.9 a.30 normal 
2 
% Body Fat 
overweight obese 
MALES 
Dietary 9.6±5.7 9.5± 4.5 9.3 ± 4 13.7 8.9 ±3.7 9.0 ±4.1 
line 
(2) (2) (8) (1) (2) O) 
Serum 100± 30 120± 40 240 ±330 80 90 ±0 240 ±320 
Zinc 
(2) (2) (8) (1) (2) (9) 
Dietary 2.1±1.6 4.1 ±0.7 1.8 ± 1.6 3.2 2.9 ±2.3 2.0 ±1.7 
Copper 
(2) (2) (8) (1) (2) (9) 
Serum 130 ±40 120 ± 2 0 110 ±17 160 140 ±7 110±10 
Copper 
(2) (2) (8) (1) (2) (9) 
Zn/Cu 0.8± 0.5 1,0± 0.5 2.3 ± 3.7 0.5 0.67 ±0.03 2.3 ±3.4 
ratio 
(2) (2) (8) (1) (2) (9) 
Dietary FEMALES 
Zinc 9.3± 4.0 8.6± 2.5 9.4 ±3.2 • 8.5 ±1.6 9.2 ±3.3 
Serum 
(12) (12) (11) (2) (33) 
Zinc 170± 21 0 130 ±80 140 ±70 110±10 150 ±140 
Dint art/ 
(12) (12) (11) (2) (33) 
i/ioi i y 
Copper 2.2± 1.5 2.2± 2.1 2.0 ±1.1 2.5 ±2.2 2.1 ±1.6 
(12) (12) (11) (2) (33) 
Serum 150 ±40 1 10 ±20 130 ±0.2 140 ±30 130 ±40 
Copper 
(12) (12) (11) (2) (33) 
Zn/Cu 1.1± 1.2 1.2± 0.6 1 ±0.7 0.8 ±0.2 1.2 ± 0.9 
ratio 
(2) (12) (12) (11) (33) 
- 2 
weight (kg)Overwelght is 25-29.9 kg-m weight for height. 
1. BMI= 2 
height (m) - 2 
Obesity Is greater than or equal to 30 kg-m weight for height. 
2. Percent body fat estimated from sum of four skinfolds (Durnln 
and Womersley, 1973). Overweight is 20-28 percent and 22-30 
percent for males and females, respectively. Obesity Is greater 
than 28 percent and greater than 30 percent for males and females, 
respectively. 
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Table A-13 
Wllcoxon Two Sample Test of Minerals bv Zinc Supplementation 
of Males 
Variable Medians for Wllcoxon Approximate 
Zinc Placebo S Value Z Score P value 
Initial 
Serum 
Zinc 
(n) 
117 110 14.00 0.00 1.00 
3 (5) 
Final 
Serum 70 51 -0.53 °-59 
ZlnC (3) (5) 10.00 
(n) 
Initial 
Serum 
Copper 
(n) 
110 
(5) 
120 
(7) 
Final 
Serum 
Copper 
(n) 
80 
(3) 
55 
(5) 
33.00 0.00 1.00 
16.00 1.24 0.21 
Initial 
Dietary g 1Q 80Q Qig Q85 
Zinc 
(n) (3) (5) 
Initial 
5 ' ® t a r y  2  2  2 8 . 0 0  - 0 . 6 4  0 . 5 1  
Copper 
(") (5) (7) 
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Table A-14 
Wllcoxon Two Sample Test of Minerals bv Zinc Supplementation of Females 
Variable 
Medians for Wllcoxon Approximate 
Zinc Placebo S Value Z Score P value 
Initial 
Serum 
Zinc 
(n) 
122 
( W )  
107 
(9) 
84.5 -1.01 0.98 
Final 
Serum 
Zinc 
(n) 
85 
(12) 
89 
(9) 
58.5 0.09 0.92 
Initial 124 146 
Serum 
Copper (17) (17) 
(n) 
290.0 -0.51 0.60 
Final 
Serum 
Copper 
(n) 
Initial 
Dietary 
Zinc 
(n) 
56 
(12) 
(12) 
90 
(12) 
75.5 0.42 0.67 
96.0 -0.14 0.88 
(9) 
Initial 
Dielary 2 2 346.0 1.30 0.19 
Copper 
C> (5) (7) 
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Table A-15 
Wllcoxon Two Sample Test of Walk Time by Subject Zinc Supplementation and 
Gender 
Variable Medians for Wllcoxon Approximate 
Zinc Placebo S Value Z Score P value 
Initial 
Walk 
Time 
( n )  
Final 
Walk 
Time 
( n )  
16 
(3) 
15 
(3) 
15 
(5) 
15 
(5) 
MALES 
12.0 
8.0 
-0.30 
0.19 
0.7 
0.8 
Initial 
Walk 
Time 
( n )  
Final 
Walk 
Time 
( n )  
16 
(12) 
15 
(9) 
14 14 
(12) (7) 
FEMALE? 
90.0 
65.0 
-0.60 
-0.4 
0.5 
0.70 
